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Environmental triggers, such as viral infection and environmental toxins, have been proposed to 
initiate the autoimmune disease of Type 1 Diabetes (T1D), however, the mechanism is unknown.  
The identification of novel autoantigens may provide insight to the mechanism of environmental 
triggers and pathogenesis of T1D.  I identified the antigen recognized by the diabetogenic BDC-
2.5 T cell clone using a novel in vivo reconstitution system, Restricted Immune System via 
Adoptive Transfer (RISAT).  In RISAT, immunodeficient mice are adoptive transferred with a 
single T cell clone and an open repertoire of B cells.   Reconstituted mice are immunized with an 
antigenic protein preparation.  This system will drive an antibody response to the cognate antigen 
for the T and B cell through the co-stimulatory pathways involved in linked recognition.  For the 
BDC-2.5 RISAT, non-obese diabetic (NOD).Rag-/- mice were adoptive transferred with the 
diabetogenic BDC-2.5 T cells and NOD B cells and then immunized with an antigenic beta cell 
membrane preparation (βmem) to drive an antibody response. The resulting antibodies 
recognized the endoplasmic reticulum (ER) stress associated protein glucose regulated protein 78 
(GRP78) from βmem.  To determine if ER stress plays a role in the antigenic response of the 
BDC-2.5 T cell clone, the non-antigenic NOD insulinoma cell line, NIT-1, were treated with 
thapsigargin, which induces ER stress.  The treatment of NIT-1 with thapsigargin led to 
increased GRP78 synthesis, correlating with antigenic recognition by the BDC-2.5 T cell clone.  
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The antibodies from the BDC-2.5 TCR-Tg recognizes a subset of GRP78 which is modified with 
phosphoserine.  The data presented in this thesis demonstrates a mechanistic link between ER 
stress and environmental triggers leading to the initiation of TID through the novel autoantigen, 
GRP78.  Also the technique, RISAT, can be used to identify additional potential autoantigens of 
isolated T cell clones in both T1D and other autoimmune diseases. 
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1.0  INTRODUCTION 
1.1 DIABETES & GLUCOSE METABOLISM 
Diabetes is a metabolic disorder that affects how the body metabolizes glucose due to altered 
insulin production or sensitivity.  Typically, food is broken down into glucose, a form of sugar in 
the blood.  The hormone insulin is responsible for facilitating the transport of the glucose into 
cells, which use it for energy and growth. As the main site of hormone regulation of blood 
glucose, the pancreas, an endocrine organ, is comprised of several cell types that secrete specific 
hormones to regulate blood glucose levels (Figure 1.1).  
There are three pancreatic cell types, which secrete hormones into the blood to regulate 
blood glucose.  The alpha cells secrete glucagon during a state of low blood glucose, or 
hypoglycemia.  Glucagon signals the liver to convert glycogen into glucose for release into the 
blood.  The beta cells produce and secrete insulin.  Elevated blood glucose levels, or 
hyperglycemia, activates secretion of insulin.  Insulin signals liver and muscle cells to take up 
and store excess glucose in the form of glycogen.  This also leads to fat cell up take of blood 
lipids that are converted into triglycerides.  Lastly, the delta cells produce somatostatin, which is 
responsible for the release of both glucagon and insulin.  In individuals with normal metabolism, 
after a meal, insulin is released to activate cells to utilize and store glucose.  After several hours 
when blood glucose levels are starting to decrease, glucagon is secreted causing the release of  
 2 
 
 
 
 
Figure 1.1  Pancreatic hormones regulate blood glucose. Regulation of blood glucose or sugar 
level is regulated by glucagon and insulin.  Insulin acts on tissue cells to stimulate glucose 
uptake from blood lowering blood glucose.  Low blood sugar promotes glucagon secretion.  
Glucagon stimulates the breakdown of glycogen to glucose in the liver.  Glucose is released into 
the blood.  High blood glucose promotes the release of insulin.  1 
 
 
 
 
                                                
1 From www.howstuffworks.com/ diabetes1.htm  Courtsey of HowStuffWorks.com 
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stored glucose.  The importance of this ability to tightly regulate blood glucose levels has 
allowed humans to survive periods of feast and famine. 
1.2 NON-AUTOIMMUNE DIABETES 
There are 3 main types of Diabetes: Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), and 
gestational diabetes.  The primary difference between the three types of diabetes is how insulin is 
produced and metabolized.  The most common form of diabetes is T2D with approximately 90 to 
95 percent of the disease falling under this classification (1).  Previously, T2D was only 
diagnosed in older individuals; however, more children and adolescents are being diagnosed with 
T2D.  This shift in the onset of T2D correlates with an increasing population of overweight 
children.  At onset, individuals with T2D produce insulin levels equal to non-diabetics, however 
they have lost the ability to utilize insulin efficiently and consequently suffer from insulin 
resistance.   
The third type of diabetes, gestational diabetes, occurs in 3 to 8 percent of pregnant 
women in the United States during the last trimester.  It develops due to insufficient insulin 
production and/or changes in hormones due to pregnancy.  After the baby is born, gestational 
diabetes usually disappears.  These individuals are at a higher risk of developing T2D.2 
 
                                                
2 http://www.diabetes.org/gestational-diabetes.jsp 
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1.3 TYPE 1 DIABETES  
T1D, also known as Insulin-dependent diabetes mellitus (IDDM) or juvenile-onset-diabetes, 
accounts for 5 to 10 percent of diabetes in the United States (2).  The disease is characterized by 
the autoimmune destruction of the islet-beta cells responsible for the production of insulin, 
typically, at a young age.  The average age of onset is 20 years old with individuals as young as 
newborn to 30 years old (3).  The destruction of the beta cell mass by the immune system leads 
to a lack of insulin production, unregulated glucose metabolism and hyperglycemia.  As shown 
in Figure 1.2, diabetes is not clinically recognized until 80 to 85% of beta cell mass has been 
destroyed (2, 3), therefore, newly diagnosed patients are left with exogenous insulin injection or 
islet replacement therapy as their only available treatment option. As new cellular and genetic 
markers and therapies become available, the goal is to identify diabetes either before any damage 
is done to the beta cell mass or while the majority of the beta cell mass is intact. 
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Figure 1.2 Beta cell loss corresponds with the level of autoreactivity in T1D. The progressive 
loss of beta cell mass (black line) correlates with an increased frequency of pathogenic CD4+ and 
CD8+ T cells (gray line). When approximately 85–90% of the beta cell mass has been destroyed, 
overt diabetes is manifested. Adapted from (4). 
1.3.1 Insulin Replacement Therapy 
Since first being isolated in 1920, exogenous insulin continues to be the primary treatment for 
T1D coupled with diet and exercise.  There are two options patients have for treatment: multiple, 
daily subcutaneous injections or insulin pumps programmed to deliver insulin subcutaneously.  
Most recently, companies are beginning to test new devices that use a sensor, which is inserted 
under the skin to monitor glucose levels and signal the insulin pump when to deliver insulin.  
The sensor replaces the need for multiple finger pricks to read blood glucose levels.  The sensor 
and pump work together in hope of creating an “artificial pancreas” that more closely mimics 
regulation of blood glucose. 
Besides changes in how insulin is delivered, various forms of insulin have changed how 
individuals regulate their blood glucose with insulin replacement.  The different forms of insulin 
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vary by their onset, peak time, and duration as outlined in Table 1.I.  The combination of the 
various forms of insulin allow for better regulation of blood glucose levels. 
 
 
Table 1.I. The types of insulin and their onset, peaktime, and duration.3 
Type Onset Peaktime Duration 
Rapid-acting 5 min 1 hr 2 to 4 hrs 
Regular/Short-acting 30 min 2 to 3 hrs 3 to 6 hrs 
Intermediate-acting 2 to 4 hrs 4 to 12 hrs 12 to 18 hrs 
Long-acting 6 to 10 hrs No peak 20 to 24 hrs 
 
1.3.2 Islet Replacement Therapy 
Another more experimental treatment strategy is islet replacement.  This potential therapy is 
achieved by either whole organ pancreas transplantation or isolated pancreatic islet 
transplantation. Islet transplantation has shown some success, 10% of patients at a 5-year follow-
up are able to be insulin free (5).  However, in order to avoid rejection, patients are put on an 
immunosuppressive regiment.  Suppression of the immune system can lead to undesirable 
complications such as gastrointestinal problems, bacterial and viral infections, and cancer (6).  
Another challenge of transplant therapy is a shortage of islets available for transplantation.  Of 
the 6,000-donor pancreata, less than half are suitable candidates for whole organ pancreas 
transplantation (6).  Furthermore, the remaining pancreata are subjected to experimental 
                                                
3 Adapted form the American Diabetes Association website.  www.diabetes.org 
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assessment to determine whether they can be used for islet isolation and transplantation into 
diabetic patients.  When islets are isolated from the pancreas, two to four pancreata are needed to 
isolate enough islets to regulate blood glucose (6).  Even if all donated pancreata were used for 
either whole organ or isolated islet transplantation, there would still be a shortage.  The shortage 
of viable human organs has lead to emerging research on xenotransplantation, using non-human 
animals as organ donors.  Some success has been shown with the use of pig islets for the 
xenotransplant (7). 
1.4 GENETICS OF TYPE 1 DIABETES  
It is clear that T1D is a polygenetic multifactorial disease.  Although, the presence of T1D 
susceptible genes does not equate to 100% penetrance, the importance of genetic factors is 
unmistakable.   
1.4.1 HLA Susceptibility 
There are a number of genes that have been implicated in the development of T1D.  One of the 
most studied markers is the human leukocytes antigen (HLA) or the human major 
histocompatibility complex (MHC) that is encoded on chromosome 6.  This marker is an 
attractive target because it has been determined that it is the major locus for type 1 diabetes 
susceptibility providing up to 40-50% of the inheritable diabetes risk (1, 2).  HLA-A, -B, and –C 
encode for the MHC Class I molecules that are expressed on most cell types and are critical for 
the presentation of endogenously derived antigens as a result of infection by intracellular 
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pathogens.  They recognize and present antigens from sources the immune system sees as 
foreign, i.e. bacteria, viruses, parasites, self-proteins in autoimmunity and donor proteins in 
transplantation.  HLA-DR, -DP, and –DQ encode for the MHC Class II molecules expressed on 
antigen presenting cells (APC).  Antigens presented via Class II are recognized by CD4+ T 
lymphocytes with Class I recognized by CD8+ T lymphocytes.  
T1D is an inheritable autoimmune disease with association between certain HLA loci 
leads to an increased susceptibility and/or protection against development of disease.  Certain 
HLA loci such as DQB1*0602 alleles have demonstrated protection against T1D with 20% of 
the general population expressing this haplotype.  Only 1% of type I diabetics express 
DQB1*0602 (8).  While HLA-DR3 or DR4 are expressed by 45% of the general population, 
94% of T1D patients express these HLA (3).  It is interesting to note that the association of HLA 
with disease development decreases in strength with increasing age of onset (9).   
1.4.2 Non-MHC Genes 
Besides HLA, the genetic importance of insulin and other non-MHC genes has been researched.  
Polymorphisms in the IDDM2 locus are associated with risk of T1D.  IDDM2 codes for variable 
nucleotide tandem repeat (VNTR) 5 of the proinsulin gene or INS-VNTR5.  There are three 
classes of INS-VNTR5.  Class I contains 26-63 repeats up to 570 bases in length.  Class III 
contains 140-200 repeats up to 2,200 bases in length with the length of Class II falling between 
the lengths of Class I and Class III.  Class III, or long-form of INS-VNTR5, is protective against 
development of T1D as it increases the amount of insulin messenger RNA expressed in the 
thymus, causing enhanced antigen-driven negative selection of insulin-specific autoreactive T 
cells.  Class I INS-VNTR5 increases T1D susceptibility as it decreases the amount of insulin 
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expressed in the thymus (2).  Additional genes have been investigated for their genetic role in the 
development of T1D, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), interferon 
induced with helicase C domain 1 (IFIH1), inositol 1,4,5-triphosphate receptor 3 (ITPR3), IL-2 
receptor, protein tyrosine phosphatase nonreceptor type 22 (PTPN22) (1, 2).  The 1858T allele of 
PTPN22, an inhibitor of T cell activation, leads to increased susceptibility for T1D.  This same 
polymorphism also increases the risk for other autoimmune diseases such as rheumatoid arthritis 
and lupus erythematosus (10).  CTLA-4 plays a vital role in the immune system as a negative 
regulator of T cell activation coded on chromosome 2 at locus IDDM12.  The A6230G single 
nucleotide polymorphism in the 3’ flanking region of CTLA4 has shown to have a strong 
correlation with T1D (11). 
1.5 ENIVRONMENTAL FACTORS  
It is apparent from identical twin studies that genetic risk is not enough to develop T1D.  In less 
than 50% of cases, both identical twins develop T1D, indicating that environmental factors must 
play a critical role in penetrance of T1D (12, 13).  Some potential triggering events that have 
been proposed are drug or chemical exposure, viral infection, and certain food exposure. 
1.5.1 Viral Infections 
There is increasing evidence that infection with enterovirus, cytomegalovirus, coxsackie virus, 
parvovirus B19, and rotavirus in genetically susceptible individuals may act as a triggering 
event.  The process of such infections in initiating an autoimmune response is not fully 
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understood.  There are several popular theories on how these infections lead to diabetes onset.  
Beta cells infected with viruses, due to a pancreatic tropism or random infections, are targeted by 
the immune system to clear the viral load from the host, thus killing the beta cells (14, 15).  An 
infection may “accidentally” cause destruction of the beta cells, also known as molecular 
mimicry.  Molecular mimicry occurs when the sequence of viral proteins and native proteins 
have high homology.  The viral protein from coxsackie virus B4, 2C (CVB4-2C), shares 
homologous regions with glutamic acid decarboxylase (GAD65).  Anti-GAD65 antibody from 
diabetic patients cross-reacting with CVB4-2C can lead to molecular mimicry, as CVB4-2C 
specific lymphocytes are not able to distinguish the two proteins from one another and thus, 
mount an immune response to the self-protein (16, 17).  Another theory speculates that the beta 
cells are killed in a bystander mechanism.  Viral-specific T cells are activated and release 
cytokines such as interferon-gamma (IFN-γ), the hallmark T helper (Th) cell cytokine.  The 
production of IFN-γ could shift the balance between Th1 and Th2 cell lineages, pushing the 
generation of a previously non-activated diabetogenic Th1 cell to emerge.  Additionally, antigen 
expression on the surface of the beta cell is enhanced by IFN-γ.  Coupled with genetic 
predisposition, the autoreactive Th1 cell is able to interact with its cognate antigen and becomes 
activated leading to beta cell destruction (18, 19). 
1.5.2 Noninfectious Environmental Triggers 
Numerous studies have explored the role of noninfectious environmental triggers such as 
exposure to cow’s milk, breast-feeding, soy or wheat products, environmental toxins and vitamin 
D intake with only anecdotal results.  Individuals exposed to cow’s milk (CM) in the first year of 
infancy are more likely to develop T1D.  Conversely, individuals who are breast-fed for the first 
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year of infancy are less likely to become diabetic.  There are several key differences between 
cow and human milk (13).  Due to high levels of casein, the protein concentration is higher in 
CM.  Beta-lactoglobulin (BLG), the main whey protein component in CM is not present in 
human milk.  Bovine albumin differs in amino acid sequence from human.  There are three 
amino acid differences between bovine and human insulin, which are present in both milks. 
These differences may lead to immune system activation in an individual with autoreactive T 
cells (13). 
 Evidence for many different environmental triggers has been proposed.  It is very likely 
that just as there are many genetic components to T1D, there is not one single environmental 
trigger responsible for disease onset.  More likely, there is a common cellular event between 
various environmental triggers that initiates T1D through the induction of autoantigens.  
1.6 IMMUNOLOGY OF TYPE 1 DIABETES 
As previously mentioned, T1D is an autoimmune disease.  Autoimmune diseases are 
characterized by the immune system attacking self-tissue.  There is a break in immunological 
tolerance to allow this to happen.  Immunological tolerance is the process by which the immune 
system does not respond to an antigen and is important for preventing autoimmunity.  Tolerance 
can be divided into three distinct forms: central tolerance, peripheral tolerance and acquired 
tolerance.  As Table 1.II demonstrates there is a distinct difference between the maturation of T 
and B lymphocytes (20).    
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Table 1.II  Mechanisms of Tolerance in B and T lymphocytes.  Adapted from (20). 
 B lymphocytes T lymphocytes 
Main site of tolerance 
induction Bone marrow; periphery Thymus; periphery 
Tolerance sensitive 
stage of maturation 
Immature (IgM+ IgD-) B 
lymphocyte CD4
+CD8+ thymocyte 
Stimuli for Tolerance induction 
Central High-avidity recognition of antigen in bone marrow 
High-avidity recognition of 
antigen in thymus 
Peripheral Antigen recognition without T-cell help 
Antigen presentation 
without co-stimulators; repeated 
stimulation by antigen 
Main Mechanisms of Tolerance 
Central Apoptosis (clonal deletion); receptor editing Apoptosis (clonal deletion) 
Peripheral 
Anergy (blocked signal 
transduction); failure to enter 
lymphoid follicles 
Anergy; apoptosis 
(activation-induced death); 
suppression 
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1.6.1 Central Tolerance 
Central tolerance is the selection of immature adaptive immune cells, both T and B lymphocytes, 
which occurs during the differentiation of both subsets of immune cells (21, 22).  After central 
tolerance selection, these T and B lymphocytes seed the periphery where they take up residence 
in peripheral lymph nodes and the spleen, as well as circulate throughout the body where 
peripheral mechanisms are able to regulate their expansion.  
1.6.1.1 Principles of clonal deletion.   
Clonal deletion is the main mechanism regulating central tolerance and is comprised of negative 
and positive selection (Figure 1.3).  T lymphocytes undergo selection in the thymus. Self-
peptides are presented on the MHC of cortical thymic epithelial cells.  T cells with moderate 
affinity TCRs are signaled to differentiate and undergo positive selection; however, T cells with 
high affinity TCRs undergo negative selection, through an apoptotic mechanism.  Apoptosis-
promoting factor is upregulated, which leads to programmed cell death.  Additionally, T cells 
with low affinity TCRs are also eliminated due to “death by neglect” as they are neither signaled 
to proliferate or apoptosis (21, 22).  
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Figure 1.3  Clonal deletion of lymphocytes.4 
 
 
 
 
 
                                                
4 adapted from http://www-immuno.path.cam.ac.uk/~immuno/part1/lec08/lec8_97.html 
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1.6.2 Peripheral Tolerance  
Not every protein in the body is expressed in the thymus or bone marrow, therefore, to further 
reduce autoreactive lymphocytes in circulation, lymphocytes are further selected against self-
tissue once they have migrated into the periphery by peripheral tolerance mechanisms.  There are 
at least four known mechanisms responsible for peripheral tolerance: anergy, ignorance, 
regulation and deletion.   
1.6.2.1 Clonal Anergy and Adaptive Tolerance.   
Anergy is the state of non-responsiveness by T and B cells to a specific antigen.    In T cells, 
anergy is simply characterized by normal IL-2 receptor expression but insufficient IL-2 
production (23).  T cell anergy can be divided into two broad categories: clonal anergy and 
adaptive tolerance or in vivo anergy (24).  Clonal anergy arises from incomplete T cell 
activation.  A block in the Ras/MAP kinase pathway maintains this arrest state.  T cells can be 
rescued from anergy by addition of IL-2 or anti-OX40 signaling.  For CD8+ T cells, clonal 
anergy does not inhibit the effector functions.  In adaptive tolerance, naïve T cells are stimulated 
in an environment deficient in costimulation or high coinhibition occurring in either the thymus 
or the periphery.  T cells proliferate and differentiate to varying degrees, however, in the 
presence of persistent antigen, T cells downregulate proliferation and differentiation.  A block in 
tyrosine kinase activation, which inhibits calcium mobilization, results in anergy.  Additionally, 
signaling through the IL-2 receptor is blocked.  Adaptive tolerance reverses in the absence of 
antigen (25).     
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1.6.2.2 Regulation.   
Regulatory T (Treg) cells achieve suppression of circulating lymphocytes.  Treg can be natural 
occurring (nTreg) or adaptively induced.  nTreg are Foxp3pos and selected for in the thymus.  
Although they recognize self-proteins, they do not lead to autoimmunity.  Adaptive Treg cells 
exit the thymus as non-regulatory Foxp3neg T cells.  In the periphery, these T cells under the right 
conditions are pushed to express Foxp3 and are able to suppress other immune cells.  It is not 
fully understood what conditions are necessary to induce this switch.  It appears that antigen-
TCR stimulation and the presence of cytokines, such as TGFβ and IL-10 play a role in the switch 
from non-regulatory to regulatory T cells (26). 
Various phenotypic markers have been identified.  Initially, CD4+ and CD25+ were 
standard markers for Treg, however, if the immune system is already activated and/or in an 
inflammatory state, CD25 or IL-2 receptor is a poor marker as it is upregulated upon activation 
(26, 27).  Low expression of IL-7 receptor α is used to identify human Treg (28).  Glucocorticoid 
induced tumor necrosis factor (GITR), cytotoxic T lymphocyte associated receptor (CTLA)-4, 
lymphocyte activating gene 3 (LAG3), CD45RB and neuropilin are additional markers for Treg, 
however, they are also expressed on other T cell populations (26).  The most specific Treg 
marker is the forkhead box transcription factor (Foxp3) (29-31).  When traditional CD4+ and 
CD8+ are induced to express Foxp3, they are reprogrammed to become suppressors (32).  
Although, Treg secretes IL-10, direct contact, not secretion of cytokines, is required for 
suppression of other immune cells, primarily APC.  CTLA-4 on the Treg surface triggers the 
production of indolamine 2,3-dioxygenase (33) that generates an immunosuppressive 
environment (34).  Treg are present in T1D (35), however, it remains to be seen if there is a 
defect in T1D Treg that leads to immune system dysregulation. 
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1.6.2.3 Ignorance.   
Ignorance occurs when a T or B lymphocyte fails to respond to its cognate antigen, even when 
the antigen is present in circulation.  If the antigen is present at a low concentration, the receptor 
occupancy threshold that is necessary to trigger a response may not be met.  Thus the 
lymphocyte does not sense the antigen.  Another reason for ignorance is that the antigen is 
present in an immunologically privileged site, such as the eye, brain, testis and uterus.  Cells in 
immunologically privileged sites express FasL on their surface, which upon binding signals 
cytotoxic T cells to apoptosis (36).  Additionally, molecular mimicry can induce ignorance as the 
immune system sees foreign proteins as self due to sequence similarities.    
1.6.3 Acquired Tolerance 
Acquired tolerance is beyond the scope of this thesis, though for completeness, acquired 
tolerance is the immune system’s tolerance for external antigens i.e. in transplantation.  Acquired 
tolerance occurs through the mechanisms of ignorance, regulation, anergy, and apoptosis (37).  
Therapeutic treatments of transplant patients aim to induce tolerance to eliminate rejection of 
donor tissue. 
1.7 B CELL DEVELOPMENT AND ANTIBODY MATURATION 
Similar to T lymphocytes, B lymphocytes go through clonal deletion, however this is achieved in 
the bone marrow.  Immature B cells express surface immunoglobulin M (IgM) as their antigen 
receptor or B cell receptor (BCR).  If the IgM molecules are able to crosslink with their cognate 
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antigen during development in the bone marrow, the immature B cell undergoes receptor 
rearrangement, or receptor editing.  If, after receptor editing, the immature B cell still recognizes 
self-proteins, it becomes apoptotic.  This mechanism leads to immature B cells that do not 
recognize self-proteins in the periphery.  
In the periphery, the immature B cells undergo further selection against self-proteins.  
Immature B cells that fail to react against self-proteins mature into mature B cells that express 
IgD in addition to IgM.  The naïve B cells are able to bind foreign proteins or self-proteins on its 
B cell receptor (BCR).  Upon recognition of its cognate antigen, the naïve B cell is activated and 
expresses CD40 on its surface (Figure 1.4).  T helper cells, Th, are able to interact with the B 
cell through the CD40L and CD40 (38).  This interaction is only achieved if the Th and B cell 
are able to bind their cognate antigen at the same time.  The B cell will present the antigen on its 
MHC class II allowing the Th cells to bind the antigen on its T cell receptor (TCR).  The Th cell 
secretes cytokines to stimulate proliferation of the B cell.  The release of IFN-γ promotes IgG 
isotype switching (39).  The B cell matures to a plasma cell that secretes IgG antibodies, which 
are able to diffuse into the blood and tissues (36, 40).   
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Figure 1.4  Interactions of T and B cell in antibody isotype switching. 
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1.8 AUTOIMMUNITY: BREAKDOWN OF THE IMMUNE SYSTEM 
 Autoimmunity is characterized by a break in both central and peripheral tolerance resulting in 
the recognition of self-tissue as foreign.  The immune system is a dynamic system with the 
above-mentioned mechanisms occurring simultaneously.  In autoimmunity, it is not the failure of 
a specific branch of tolerance that leads to the progression of this disease (41).  In T1D, 
autoreactivity ensues as a result of the escape of self-reactive T cells that recognize beta cell 
antigens.  Autoreactive B cells fail to be selected against in the bone marrow.  Once in 
circulation the autoreactive lymphocytes evade peripheral tolerance detection.  When B cells 
come across their cognate antigen, the lymphocytes are stimulated and proliferate.  The B cells 
will produce autoantibodies that mark the beta cells for destruction. Though Treg are present in 
the circulation, they are unable to suppress the autoreactive lymphocytes from initiating the 
destruction of beta cells (26). 
1.9 AUTOANTIBODIES & AUTOANTIGENS ASSOCIATED WITH T1D 
Islet-cell cytoplasmic autoantibodies (ICA) were first discovered in T1D patients in 1974.  Sera 
from type I diabetic patients revealed detectable islet proteins in frozen pancreas sections by 
indirect immunofluorescence.  Two of the ICA antigens were identified as glutamic acid 
decarboxylase (GAD65) and insulinoma-associated protein 2 (IA-2). The ICA 
immunofluorescence test was commonly used as the diagnostic gold standard until recombinant 
proteins for GAD65 and IA-2 became available (3, 42).  The advent of the highly sensitive and 
less cumbersome radioimmunoassay with recombinant GAD65 and IA-2 allows for a high-
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throughput assay to determine whether a patient is autoantibody positive.  This assay set a major 
milestone in the progression toward identification of patients at risk for progression to T1D prior 
to disease onset.  Insulin was identified as an autoantigen later in the development of T1D 
because during the preparation of the frozen section slides for ICA immunofluorescence test, 
insulin, along with c-peptide, is leached from the cytoplasm of the sections.  At present GAD65, 
IA-2 and insulin autoantibodies are standard markers for diagnosis of T1D.  These antibodies are 
also used to assess an individual’s risk of developing diabetes (Figure 1.5).  GAD65 and IA-2 
positive individuals demonstrate a 50% likelihood of developing T1D within 5 years (43).  When 
all three autoantibodies are present, the risk of developing diabetes within 5 years increases to 
70% (44).  
 
 
Figure 1.5  Diagrammatic representation of the effect of multiple autoantibodies (GAD65, IA-2, or insulin) on 
the risk of developing T1D. Percent diabetes represents an approximation from several longitudinal studies on first-
degree relatives of T1D patients.  Adapted from (3). 
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1.9.1 Glutamic Acid Decarboxylase (GAD65) 
More specifically, GAD is expressed in two isoforms, GAD65 and GAD67.  The molecular 
weight of GAD65 and GAD67 are 65 kDa and 67 kDa, respectively and the isoforms are 65% 
identical. GAD functions to convert glutamic acid to gamma-aminobutyric acid (GABA), a 
major inhibitory neurotransmitter.  Both isoforms are equally expressed in neurons, however, 
GAD65 is predominately expressed in the beta cells.  In beta cells, GAD is modified by lipids 
and anchored to the cytosolic face of synaptic-like microvesicles that store and secrete GABA.  
Autoantibodies present in the sera of type I diabetics recognize the middle (amino acids 245-449) 
and C-terminal (amino acids 450-585) regions of GAD65, which is 585 amino acids long.  There 
is some cross-reactivity with the autoantibodies to GAD67 (3).  GAD65 autoantibodies are 
present at the onset of diabetes and in at-risk first-degree relatives of type I diabetics (42).  Thus, 
the presence of these autoantibodies provides limited insight to the pathogenesis of the disease. 
1.9.2 Insulinoma-associated protein 2 (IA-2) 
IA-2, also known as ICA-512, is a member of the receptor-type protein tyrosine phosphatase 
family.  The predicted structure of IA-2 contains a luminal domain (amino acids 1-576), a single 
transmembrane domain (amino acids 577-601) and a cytoplasmic tail (amino acids 602-979), 
which includes a tyrosine phosphatase motif  (42).  Unlike other members of the receptor-type 
protein tyrosine phosphate family, IA-2 lacks a functional catalytic domain due to an Ala to Asp 
substitution at position 911 (3).  In addition to the pancreatic alpha and beta cells, IA-2 is 
expressed in neuroendocrine cells and is localized to the secretory vesicles of both cell types.  It 
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is speculated that IA-2 is involved in the trafficking and maturation of insulin secretory granules 
as IA-2 is found in insulin granules membranes (42).  
1.9.3 Insulin 
Insulin autoantibodies recognize “conformational” epitopes, which is an epitope that is only 
present when the protein is folded in a tertiary structure.  This is also the case with GAD65 and 
IA-2 autoantibodies.  The A and B chain of insulin is derived from preproinsulin (Figure 1.6).  
The leader peptide is removed from preproinsulin and two endoproteolytic cleavages excise the 
c-peptide region.  The B chain is processed by carboxypeptidase E (CPE) to yield its final form.  
The A and B chain are held together covalently with two disulfide bonds.  Autoantibodies, CD4+ 
and CD8+ T cells specific for insulin, all recognize epitopes on the B chain.  Due to the 
formation of antibodies to exogenous insulin following insulin replacement therapy, analysis of 
the presence of insulin autoantibodies needs to be done prior to insulin replacement.   
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Figure 1.6  T-cell epitopes for insulin, the ‘original’ autoantigen. Human preproinsulin (top 
left) and murine preproinsulin 2 (top right). Epitopes for CD4+ T cells are indicated by different 
shading patterns, and the beginning and ending residues for each epitope are labeled. Broken red 
arrows denote CD8+ T-cell epitopes. As is true for certain other beta cell antigens, certain 
preproinsulin peptides are antigenic in both humans and NOD mice (including the CD4+ T-cell 
epitope B9–23), and CD8+ T-cell epitopes overlap those for CD4+ T cells.  Human insulin 
(bottom left) and murine insulin 2 (bottom right). Disulfide bonds are represented by solid black 
lines. Adapted from (42). 
 
1.9.4 Islet Cell Autoantigen of 69 kDA (ICA69)  
The autoantibodies of islet cell autoantigen of 69 kDA (ICA69) have the potential to yield 
tremendous insight regarding the pathogenesis of the T1D, as they are detectable in prediabetic 
individuals.  ICA69 was first discovered from the sera of three prediabetic relatives of a T1D 
patient; all three later became diabetic (45).  Screening of sera from subjects at risk for T1D were 
positive for ICA69 autoantibodies in 43% (10 of 23) of ICA+ first-degree relatives, who later 
developed T1D.  The potential of ICA69 being a marker indicative of development of T1D, was 
somewhat undermined by studies conducted in the non-obese diabetic (NOD) mouse, which 
demonstrated that ICA69null NOD mice developed diabetes with the same kinetics as wild-type 
NOD littermates (46).  It, however, has yet to be determined if the role of ICA69 is the same in 
humans, but it remains a very hot topic in T1D research.      
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1.9.5 Other autoantigens 
Numerous other autoantigens have been identified through autoantibodies and autoreactive CD4+ 
and CD8+ T cells.  The target antigens are located in a variety of compartments with various 
functions in the beta cells as shown in Figure 1.7.  Nine out of twenty-four antigens are 
associated with the insulin secretory granules.  Heat shock protein 70 (HSP-70) and islet-specific 
glucose-6-phosphatase catalytic subunit-related protein (IGRP) are two autoantigens that are 
primarily located in the ER and thus are of special interest in this thesis.   
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Figure 1.7  Subcellular localization of beta cell antigens. The proteins and lipids to which 
T1D patients and/or NOD mice have demonstrated immune responses are each denoted by a 
different symbol in this schematic representation of a beta cell.  The position of each symbol 
within the beta cell indicates the cellular compartment in which that particular antigen is 
primarily localized.  Although antigens are located throughout the beta cell, the highest number 
sof antigens (nine of 24) are associated with the secretory granules  (42). 
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1.9.5.1 Heat shock protein 70 (HSP70).   
HSP70 antibodies and autoreactive T cells have been detected in children (under the age of 18) 
with T1D.  Two major epitopes, p27 (amino acids 391-410) and p35 (amino acids 511-530), 
have been identified for HSP70 (47).  It is not known how HSP70 becomes antigenic, however, 
it has been documented that even control individuals have some detectable IgG specific-
antibodies for HSP70 with 45% of type I diabetic children expressing significantly higher HSP70 
IgG levels (47).  Abulafia-Lapid et al proposes that this may be due to immunological 
homunculus (48), naturally occurring autoimmunity in healthy individuals (47).  One could 
speculate that aberrant peripheral regulation of these naturally occurring autoimmune cells 
contributes to organ-specific autoimmunity of T1D. 
1.9.5.2 Islet-specific Glucose-6-phosphatase catalytic subunit-Related Protein (IGRP).   
IGRP specific CD8+ T cells have been isolated from NOD islets at the earliest stages of 
detectable islet infiltration (49), supporting the notion that IGRP may be an early target in the 
pathogenesis of T1D.  Additionally, the presence of CD4+ and CD8+ T cells and the CD8+ T cell 
epitopes have been confirmed in humans and NOD mice (49-52).  Most recently, a considerable 
effort has been put forth toward understanding the role of ER stress in the induction of increased 
IGRP expression (53). 
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1.10 TYPE 1 DIABETES MOUSE MODEL  
 
1.10.1 Non-Obese Diabetic (NOD) Mouse Model 
With the diagnosis of diabetes being made when approximately 80% of beta cell mass has been 
destroyed by the immune system, animal models have played a pivotal role in elucidating the 
pathogenesis of T1D.  The non-obese diabetic (NOD) mouse is the most commonly used mouse 
model in T1D research (12, 42, 54, 55).  The NOD mouse was developed unexpectedly through 
the breeding of a cataract-free CTS (Cataract Shionogi mouse) strain (12, 56).  The utility of the 
NOD mouse model is born out of the similarities this strain has to human T1D, in that NOD and 
humans spontaneously develop diabetes, produce islet-specific antibodies, and generate T cells 
that recognize islet-beta cell associated antigens leading to beta cell destruction.  Beta cell loss 
leads to hyperglycemia and clinically apparent diabetes.  The presence of multiple susceptibility 
loci has been associated with the progression of T1D in the NOD mouse.  For example Idd1 has 
mapped to the MHC II region.  The NOD mouse has a distinct haplotype at the MHC II, which is 
characterized by the unique class II molecule I-Ag7.  This class II molecule is unique in that the 
aspartic acid at position 57 in the ß-chain is substituted with a non-aspartic acid residue, which 
has been hypothesized to play a major role in the predisposition to T1D (12).  Furthermore, it is 
known that NOD mouse’s macrophages have a number of defects including processing and 
presentation (57, 58).  Specifically, NOD macrophages are defective in engulfing and clearing 
apoptotic bodies that result from dead cells.  It is proposed that poor clearance leads to the 
presentation of self-proteins to the autoreactive T and B cells.  Approximately 80% of the female 
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and 20% of male mice in a NOD colony are diabetic by 6 months of age; however, the average 
age of onset is 12 weeks of age (12, 54).  The sex difference in the diabetes incidence is unique 
to the NOD.  It has been proposed that this is due to the effect of sex hormones.  This is 
supported by studies in which castration increases the incidence of diabetes in male mice.  For 
female mice, ovariectomy and administration of testosterone decreases the incidence of diabetes 
(59, 60).  These studies demonstrate that increased estrogen levels lead to higher levels of T1D 
incidence and testosterone has a protective effect. 
1.10.2 BDC-2.5 T Cell Clone   
A number of cellular reagents from the NOD mouse have been isolated and utilized 
experimentally to elucidate the mechanism of T1D. For example, the generation of autoreactive 
T cells have been instrumental in increasing our understanding of the T cell mediated 
pathogenesis that occurs in the T1D autoimmune attack.  One particular panel of T cell clones 
that have been studied extensively is the panel of autoreactive T cells outlined in Table 1.III.  
These autoreactive T cells induce diabetes when adoptively transferred into mouse strains such 
as the NOD, allowing studies to investigate early pathogenesis of T1D before disease onset.  One 
diabetogenic T cell clone that has been extensively researched is the BDC-2.5 T cell clone, 
derived in 1989 (61).  The BDC-2.5 T cell clone has a known T cell receptor (TCR), vβ4 vα1, 
and was originally derived from the spleen and lymph node of a newly diabetic NOD female.  A 
beta granule membrane antigen is present in the context of the NOD MHC class II IA-g7 (62). 
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Table 1.III  Islet-specific T cell clones. Adapted from (61). 
 
 
 
In vitro response to NOD APC and 
islet-cell antigen  
Clone 
CD4/ 
CD8 TCR 
No 
Ag 
NOD 
IC 
Non- 
NOD IC Rat IC βTC3 
Islet 
graft 
damage 
BDC-2.4 +/– n.d. + + +  + – 
BDC-2.5 +/– Vβ4 Vα1 – + + – + + 
BDC-4.6 +/– n.d. – + + –  + 
BDC-4.12 +/– 
Vβ19 
Vα[4.12] 
– + +    
BDC-5.2 +/– Vβ6 Vα12 – + + +   
BDC-5.10 +/– 
Vβ4 
Vα (n.d.) 
– + + – + + 
BDC-6.3 +/– Vβ4 Vα3.1 – + + – + + 
BDC-6.9 +/– Vβ4 Vα13.1 – + –   + 
Ag, antigen; IC, islet cells; n.d. not determined.  + = positive response  – no response from the T 
cell clone 
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Culturing the clone with islet cells and NOD APCs induces the production of IL-2, IFN-γ, and 
TNF-α, but not IL-4, indicative of a Th1 phenotype.  When adoptively transferred into NOD or 
NOD.scid mice between 7 to 14 days of age, animals develop extensive insulitis and 
hyperglycemia.  However, if the NOD recipient is over 3 weeks of age or an adult NOD.scid, a 
co-transfer of diabetic splenocytes needs to accompany the clone to successfully induce diabetes.  
Insulitis and hyperglycemia is a result of an autoimmune pancreatic infiltrate consisting of CD4+ 
T cells, CD8+ T cells, B cells, and macrophages. 
1.10.3 BDC-2.5 TCR-Transgenic Mouse Model 
To more invasively investigate the role BDC-2.5 plays in diabetes development, the BDC-2.5 T 
cell has been developed into a TCR-transgenic mouse.  The BDC-2.5 TCR-Tg has been bred 
onto the NOD, NOD.scid and B6g7 backgrounds (Figure 1.8).  On the NOD background, only 
10-15% of BDC-2.5/NOD animals spontaneously develop diabetes. By 3-5 weeks of age 100% 
of BDC-2.5 mice bred to the NOD.scid background develop diabetes (63).  The BDC-2.5/B6g7 
begins to develop diabetes at 3 weeks of age, with the average onset at 6 weeks.  The diabetes 
incidence at 10 weeks is approximately 60% in the BDC-2.5/B6g7.  BDC-2.5/B6g7 animals that 
were free of diabetes at 10 weeks of age remain resistant (64).  
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Figure 1.8  Diabetes Incidence for the BDC-2.5 TCR-Tg on NOD, NOD.scid, and B6g7 
backgrounds. Adapted from (63-65). 
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1.11 PROTEIN TRAFFICKING 
Protein trafficking is critical to the cellular well being due to the various compartments of the 
cell.  The targeting of newly synthesized proteins to their correct compartment or organelle is 
achieved by sorting or signal sequences.  In the absence of a specific signal sequence, protein is 
transported to the cytoplasm.  Nuclear proteins are targeted by nuclear localization signal and are 
directly translated into to the nucleus through the nuclear pore.  Resident endoplasmic reticulum 
(ER) proteins contain a “KDEL” sequence that retains it in the ER. 
Briefly, the translation of mRNA in the cytoplasm occurs on free ribosomes.  Signal 
sequences can either be translated in a continuous stretch of 15-60 amino acids or in a signal 
patch.  Signal patches are comprised of several shorter stretches of amino acid that, when the 
protein is folded, signals the protein to be transported to the correct compartment (Figure 1.9).  
These signal sequences allow for signal recognition particles (SRP) to bind ribosomes and halt 
further translation.  The SRP binds to docking proteina on the rough ER (RER) (65) and the 
signal sequence is inserted into the RER.  With the protein synthesis resuming, the polypeptide 
chain is pulled through the membrane.  The newly synthesized protein is now in the lumen of the 
ER.  Some signal sequences are cleaved from the protein by signal peptidases.  Signal patches 
generally are not removed from the protein.  The ribosomes and SRP are released and recycled 
for further protein synthesis.  In the ER, proteins undergo the posttranslational modifications of 
N-linked glycosylation and GPI-linkage.  It is important to note that only proteins that are 
correctly folded are transported out of the ER.  Misfolded proteins are bound by molecular 
chaperones and targeted for degradation in proteasomes.  Further posttranslational modifications 
and sorting occurs in Golgi.  Protein enters the Golgi on the cis face.  As the protein is processed, 
it is transported through the Golgi to the trans face.  Resident ER proteins are returned to the ER 
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in the vesicles.  Secretory proteins are also packaged into vesicles for export to the cell surface 
(66).    
Figure 1.9 Signal Sequences. A) A signal sequence can be a continuous stretch of animo acids. 
B) Or a signal patch may be responsible for the targeting of a protein.  Signal patches are made 
up of several regions that, when the protein is folded, signal for transport.  Adapted from (66). 
 
1.12 ENDOPLASMIC RETICULUM STRESS PATHWAY 
The cellular organelle, ER, is an interconnected network of tubules, vesicles, and cisternae that 
connects the nucleus to the Golgi.  As previously mentioned, the ER is the site of protein 
translation, protein folding, and posttranslational modifications.  Secreted and membrane 
associated proteins pass through the ER on their way to the Golgi for further processing.  The ER 
also acts as a storage location for calcium, glycogen, steroids, and other macromolecules (67).  
Importantly, the ER contains numerous molecular chaperones and catalysts to aid in the folding 
and posttranslational modifications of proteins (68).   
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Cells have developed signaling pathways and effector mechanisms to deal with the 
temporal and developmental variation in ER protein load.  The ER stress pathway regulates this 
balancing act in four specific ways, 1) induction of ER chaperones through the unfolded protein 
response (UPR), 2) translational attenuation, 3) ER associated degradation (ERAD) (69), and 4) 
apoptosis (Figure 1.10) (70).   
 
Figure 1.10 The ER stress pathway. In order to cope with the buildup of misfolded proteins, 
there are four cellular responses. A. Induction of ER chaperones and accessory proteins.  B. 
Translational attenuation. C. Misfolded proteins are degraded through ERAD.  D. Activation of 
apoptosis.  Adapted from (70). 
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1.12.1 Unfolded Protein Response (UPR) 
Upon accumulation of unfolded and misfolded proteins, UPR is activated in order to upregulate 
ER chaperones.  The increased number of chaperones is able to re-process the proteins that were 
unfolded or misfolded.  The ER stress transducer proteins, inositol requiring-1 (IRE-1), 
activating transcription factor-6 (ATF6), and PKR-like ER kinase (PERK) are activated.  IRE1 
and PERK are released from GRP78 (Glucose regulated protein 78 kDa)/BIP (Immunoglobulin 
binding protein).  ATF6 is activated by a two-step cleavage by Site-1 protease (S1P) and Site-2 
protease (S2P).  IRE1 initiates XBP-1 to activate the transcription of target genes for molecular 
chaperones and accessory proteins such as catalysts.  ATF6 and PERK initiate the transcription 
factors, p50ATF6 and ATF4, respectively, which activate transcript of additional molecular 
chaperones and catalysts (68, 70, 71). 
1.12.2 Translational attenuation 
Translational attenuation lowers the load of client proteins by halting protein translation, thus 
giving the cell more time to process the unfolded proteins.  PERK induces phosphorylation of 
eukaryotic initiation factor-2a (eIF-2a), which blocks translation initiation (70, 71).   
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1.12.3 ER associated degradation (ERAD) 
ERAD is the pathway in which misfolded are designated for degradation.  Unsalvageable 
proteins are transported to the proteasome by molecular chaperones.  Misfolded proteins are 
transported out of the ER by GRP78 through the Sec61 complex to the cytosol.  The misfolded 
proteins are ubiquitinated marking them for degradation by the 26S proteasome (70, 71).   
1.12.4 ER stress-apoptosis 
If a cell is unable to deal with the unfolded proteins, the ER stress pathway will initiate 
programmed cell death, or apoptosis (72).  There are three known apoptosis pathways triggered 
by ER stress: (1) CHOP(C/EBP homologous protein)/GADD153, pathway, (2) cJUN NH2-
terminal kinase (JNK) pathway, and (3) caspase-12 pathway.  CHOP is the transcription factor 
that regulates one of the pathways.  CHOP levels are temporally regulated from limited detection 
to strong expression upon ER stress activation.  CHOP promotes apoptosis in response to ER 
stress as determined by overexpression and targeted disruption of the CHOP gene (70, 73, 74).  It 
is not known what the exact targets of CHOP are that result in apoptosis, however, Marciniak et 
al demonstrate that CHOP acts on GADD34 to promote protein synthesis and alter the oxidation 
balance in the cell leading to ERO1 (ER oxidase 1) activation (75). 
The JNK pathway is another means that leads to ER stress-apoptosis.  JNKs are signal 
transduction proteins that regulate gene expression and participate in apoptosis/survival 
pathways in response to stressors.  Upstream of JNK activation, the ER stress protein, Ire1 
recruits TRAF2 and ASK1.  The three proteins form a complex to activate JNK to induce 
apoptosis (70, 73).  
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The final ER stress-apoptosis pathway is through caspase activation, specifically caspase-
12 in rodents (73, 76).  Caspase-12 is activated by m-calpain (77), IRE1a/TRAF2 (78), or 
caspase-7 (79).  Death receptor-mediated or mitochondria-targeted apoptotic signals are not 
responsible for caspase-12 activated when stimulated by ER stress (70, 73). 
1.13 ER STRESS AND THE BETA CELL 
Secretory cells, like islet beta cells and plasma cells, have a more developed ER in order to 
manage the continuous pressure of protein processing, which leads to continuous ER stress, due 
to upregulation of chaperones and accessory proteins required to maintain ER homeostasis (80).  
In islet beta cells, disequilibrium in the ER leading to activation of ER stress occurs in response 
to a number of cellular events.  There is increasing evidence that cytokines, reactive oxygen 
species (ROS), viral infection, and drug/toxin exposure results in activation of ER stress.  ROS 
has been shown to be important in beta cell death in T1D.  Oyadomari et al demonstrated that 
MIN6, a mouse insulinoma cell line, produces nitric oxide (NO) in response to treatment with a 
cocktail of IL-1β, TNF-α, and IFN-γ cytokines.  The production of NO correlates with the 
activation of ER stress, signified by the upregulation of GRP78, IRE1α, and PERK (74). 
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1.14 ER STRESS AND DISEASE 
The role of ER stress in the pathogenesis of various diseases has begun to be elucidated.  
‘Conformational diseases’ or ‘folding diseases’ are diseases caused by the misfolding of cellular 
protein causing aggregates that can initiate ER stress.  Neurodegenerative diseases, bipolar 
disorder, T1D, T2D, atherosclerosis, ischemia, heart disease, liver disease, kidney disease, and 
other inflammatory diseases have shown to alter ER stress response.  During T1D, inflammation 
plays a critical role in disease progression and, in some instances, is associated with ER stress.  
During inflammation NO-induced apoptosis, mediated by ER stress and CHOP, has been 
documented in beta cells (70, 81, 82) (69, 75).  In the inflammatory disease, rheumatoid arthritis, 
GRP78 is a target autoantigen for T and B cells.  Blass et al. reported that 63% of the 400 RA 
patients tested for T cell reactivity to GRP78 demonstrated specific T cell reactivity, when 
challenged with biochemically purified GRP78 from mammalian cells, in addition to GRP78 
autoantibodies (83).  
 
 
 
 
 
 
 
 
 40 
2.0  HYPOTHESIS AND SPECIFIC AIMS 
It is long been proposed that there are environmental triggers that initiate the antigen-driven 
autoimmunity, which is responsible for the loss of beta cell mass in Type 1 Diabetes (T1D).  A 
number of the environmental triggers are associated with T1D, however, there does not appear to 
be a common link between these environmental triggers.  I hypothesize that identification of 
additional autoantigens will yield a greater understanding of the pathogenesis of T1D 
specifically the antigen for the BDC-2.5 T cell clone. 
 
Specific Aim 1:  Based on the concept of linked recognition, I will utilize the novel technique 
Restricted Immune System via Adoptive Transfer (RISAT) to drive an antibody response to the 
cognate antigen for the BDC-2.5 T cell clone. 
 
Specific Aim 2: Using the antibodies from the BDC-2.5 RISAT mice, I will identify candidate 
antigens for the BDC-2.5 T cell clone.  Proteomic analysis will be used to identify the protein(s) 
recognized by the RISAT antibodies. 
 
Specific Aim 3: BDC-2.5 T cell assay will be preformed with candidate antigens to confirm their 
antigenicity to the BDC-2.5 T cell clone.  The source of antigen will be from purified 
preparations or through in vivo upregulation in the non-antigenic NIT-1 cells. 
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3.0  MATERIALS AND METHOD 
 
3.1 ANIMALS 
BALB/c, DO11.10, CB17.scid, NOD, BDC-2.5/NOD TCR-Tg, and NOD.Rag-/- mice (Jackson 
Laboratory, Bar Harbor, ME) were housed and bred under specific pathogen-free conditions in 
the animal Facility of the Rangos Research Center at the University of Pittsburgh. BALB/c, 
DO11.10, CB17.scid mice were used to develop the DO11.10 Restricted Immune System via 
Adoptive Transfer (RISAT) mouse model.  NOD and NOD.Rag-/- mice were used for the BDC-
2.5 RISAT mouse model. BDC-2.5/NOD TCR-Tg mice were used to collect serum.  Blood was 
collected for sera as approved by the University of Pittsburgh IACUC. 
3.2 T- AND B-CELL ISOLATION, T CELL CLONE CULTURE, AND ANTIGEN-
SPECIFIC T CELL ASSAY.   
T-cells from DO-11.10 mice and B cells from BALB/c and NOD mice were purified from 
spleens by negative selection using MACS magnetic beads. The T and B cell purity was greater 
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than 95% (data not shown). BDC-2.5 T-cell clones were used after restimulation in culture with 
antigen/APC and further expansion in subculture with additional IL-2 as previously described 
(84).  BDC-2.5 T cell clones were stimulated every 2 weeks with beta cell antigen and irradiated 
NOD splenocytes were used as APCs in complete media (62, 85).  The antigen was in the form 
of a βmem made from beta-cell adenomas (62).  
For antigen-specific assays, BDC-2.5 T cell clones were cultured in 96-well flat-bottom 
plates at a density of 2 x 104 cells/well, with or without 5 x 105 irradiated NOD splenocytes as 
APC and a source of antigen, such as untreated and thapsigargin treated NIT-1 cells (see below, 
under Induction and Detection of ER stress and/or Apoptosis in Cell Lines), or recombinant 
GRP78 (Stressgen; Victoria, BC) at 100µg/ml or 62.5µg/ml.  The assay plates were incubated at 
37°C for 72 hrs before the supernatants were harvested. IFN-γ production by the BDC-2.5 T 
cells was assessed by sandwich enzyme-linked immunosorbent assay (ELISA).   
3.3 RISAT RECONSTITUTION VIA ADOPTIVE TRANSFERS, IMMUNIZATION, 
AND SERA COLLECTION.   
CB17.scid mice were injected retro-orbitally with 2 x107 DO11.10 T-cells, followed by purified 
BALB/c B cells (2x107) 72 hrs later.  The immunization agents were either whole OVA or as a 
negative control, pigeon cytochrome c (PCC).  CB17.scid mice were immunized with 300µg 
OVA or 100µg PCC in Complete Freund’s Adjuvant (CFA) into the base of the tail.  On day 14, 
CB17.scid mice were re-immunized with 150µg OVA or 50µg PCC in Incomplete Freund’s 
Adjuvant (IFA), and an additional boost of 100µg OVA or 100µg PCC in IFA was administered 
at day 53.   “Pre”, “post”, “1st”, and “2nd” immunization sera were collected and on day 58, a 
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post-“3rd” bleed was collected.  The resultant sera was screened by Western blot for 
immunoglobulin production after each treatment. 
Adult NOD.Rag-/- mice were pre-bled prior to receiving 2x107 BDC-2.5 T cells (day -7) 
retro-orbitally.  Control animals received HBSS only.  On day -5 all NOD.Rag-/- animals 
received purified NOD B cells (2x107) by retro-orbital injection.   On day 0, serum was again 
collected from all animals by centrifugation (14,000 x g) of peripheral blood, and the 
reconstituted NOD.Rag-/- mice were immunized with 100µg of a βmem derived from beta cell 
adenoma cells as previously described (62), in CFA in the base of the tail (day 0).  On day 14, a 
post-“1st” immunization bleed was collected, and all mice were boosted with 50µg of βmem in 
IFA (day 14).  On day 21, a post-“2nd” boost bleed was collected.  
 
3.4 IMMUNOBLOT ANALYSIS 
50µg, unless otherwise noted, of protein was separated on a 12% SDS-PAGE prep gel using 
Mini-Protean II electrophoresis (Bio-Rad, Hercules, CA) at 150V for 1 h. Proteins were 
transferred onto 0.45µm charged polyvinylidene fluoride (PVDF) membranes using a Mini 
Trans-Blot electrophoretic transfer apparatus (Bio-Rad) at 100V for 1 hr at 4°C in Transfer 
Buffer (containing 25mM Tris-HCl, 192mM glycine, 10% methanol, pH=8.3).  Membranes were 
stained with Ponceau S stain (0.1% (w/v) in 1.5% trichloracetic acid (v/v)) to visualize protein 
bands and rinsed with 40% methanol and 7.5% glacial acetic acid to remove excess stain.  
Membranes were blocked in 5% milk in PBS containing 0.05% Tween-20 (PBST) for 1 hr at 
room temperature.  Primary antibodies, commercially available or sera, were diluted in 5% BSA 
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in PBST, then incubated with membranes overnight at 4°C.  Membranes were probed with 
secondary antibodies diluted in 5% milk in PBST and bands were detected with ECL Plus 
reagent (Amersham Pharmacia Biotech, Buckinghamshire, UK) according to the manufacturer’s 
protocol.  Phosphoserine (P-ser), phosphotyrosine (P-tyr) and phosphothreonine (P-thr) were 
detected with Sigma phospho-specific antibodies.   
3.5 SCREENING SERUM FOR AUTOANTIBODIES 
Sera from RISAT reconstituted CB17.scid, NOD.Rag-/-, NOD (2 months non-diabetic, 4 months 
diabetic, and 6 months diabetic), and NOD.BDC-2.5 TCR-Tg mice were screened for antibodies 
against either OVA or βmem.  The screening method was similar to immunoblot analysis 
described in “Immunoblot Analysis” except for the following steps.  50µg OVA or βmem were 
separated on a 12% SDS-PAGE prep gel and then transferred onto PVDF membranes.  
Membranes were blocked in 5% milk in PBST for 1 hr at room temperature.  The membrane was 
placed into the Mini-Protean II Multiscreen Apparatus (Bio-Rad).  Sera from the RISAT-treated, 
NOD or NOD.BDC-2.5 TCR-Tg mice were diluted in 5% BSA in PBST and added into a 
specific slot of the Multiscreen blotter, then incubated overnight at 4°C.  After the slots were 
flushed with PBST, membranes were removed from the apparatus and probed with goat anti-
mouse HRP secondary antibody and bands were detected with ECL Plus reagent (Amersham 
Pharmacia Biotech, Buckinghamshire, UK) according to the manufacturer’s protocol. 
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3.6 IMMUNOPRECIPITATION OF AUTOANTIGENS 
50µg of βmem, NIT-1 untreated or treated with thapsigargin (1µM or 5µM) or HeLa untreated or 
treated with thapsigargin (1µM or 5µM) lysate was incubated with 50µl NOD.BDC-2.5 TCR-Tg 
mouse sera overnight at 4°C.  The following day, 25µl of washed Protein G Sepharose (Sigma) 
was incubated with the protein:antibody complexes for 2 hrs at 4°C.  The immunoprecipitates 
were collected by centrifugation at 540x g, washed twice with RIPA (Radio-
Immunoprecipitation Assay) Buffer (containing 1% Nonidet P-40 or Igepal CA-630, 0.5% 
sodium deoxycholate, 0.1% SDS, and protease inhibitor cocktail (1x, Roche, Nutley, NJ) in 
PBS), and then heated in Laemmli buffer at 100°C for 5 min.  The immunoprecipitated proteins 
were separated on 4-20% gradient SDS-PAGE gels.  Immunoblot analysis was preformed as 
described in “Immunoblot Analysis”.   
 
3.7 PROTEOMIC ASSAYS FOR IDENTIFICATION OF CANDIDATE 
AUTOANTIGEN. 
For MALDI-ToF, protein bands on a 4-20% gradient gel were stained with GelCode® Blue 
reagent (Pierce Biotechnology, Rockford, IL).  The Proteomics Core Lab at the University of 
Pittsburgh preformed MALDI-ToF analysis on bands of interest.  For Edman analysis, protein 
bands were transferred onto 0.45µm charged PVDF membranes using a Mini Trans-Blot 
electrophoretic transfer apparatus (Bio-Rad) at 100V for 1 hr at 4°C in Transfer Buffer.   
Membranes were stained with GelCode® Blue reagent to visualize protein bands. The 
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Laboratory of John Hempel (Department of Biological Sciences, University of Pittsburgh) 
preformed Edman degradation on bands of interest.  
3.8 INDUCTION AND DETECTION OF ER STRESS AND/OR APOPTOSIS IN 
CELL LINES. 
NIT-1 cells (passage 27) (86) (ATCC, Manassas, VA) were propagated in 75-cm2 flasks at 37°C 
in culture media (CM).  Cells were fed with new medium every other day and were grown to 
confluence in the tissue culture flasks, at which time they were harvested using non-enzymatic 
Cell Dissociation Buffer (Invitrogen, Carlsbad, CA) and transferred to the appropriate culture 
dishes, either for expansion or for the described experiments.  To induce ER stress and/or 
apoptosis, cells were treated with 1 or 5µM thapsigargin for 60 min or 10, 25 or 50µM N,N,N',N-
tetrakis(2-pyridylmethyl) ethylenediamine (TPEN) for 4 hr and then washed with CM three 
times.  Cells were centrifuged and collected for biochemical assays after two washes with PBS or 
transferred to 96-well plates for T cell assays. 
Induction of ER stress was identified by immunoblotting and detecting GRP78 levels. 
50µg of NIT-1 or HeLa lysates in RIPA buffer (containing 1% Nonidet P-40 or Igepal CA-630, 
0.5% sodium deoxycholate, 0.1% SDS, and protease inhibitor cocktail (1x, Roche, Nutley, NJ) in 
PBS) were separated on a 4-20% gradient SDS-PAGE gel.  Immunoblot analysis was followed 
as described in “Immunoblot Analysis”.  The following primary antibodies were used anti-
BiP/GRP78 antibody (Stressgen; Victoria, BC, 1:1000; Santa Cruz (N-20), Santa Cruz (C-20), or 
Santa Cruz (H129); Santa Cruz, CA, 1:1000), or anti-beta actin antibody (Sigma; 1:15,000) in 
5% BSA in PBST.  Goat anti-rabbit, rabbit anti-goat and goat anti-mouse (1:15,000) IgG 
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polyclonal antibody conjugated to HRP were used as secondary antibodies.  
In order to identify the NIT-1 cells as apoptotic or necrotic after treatment with 
thapsigargin or TPEN, a quantitative fluorescent assay was performed as previously described 
(84).  Cells were harvested and transferred to a microcentrifuge tube and centrifuged for 5 min at 
200g.  Supernatants were aspirated carefully, leaving 25 µl for resuspension of the cell pellets by 
gentle shaking of the tube.  After addition of 2 µl of DNA intercalating dye mix (100 µg/ml 
acridine orange & 100 µg/ml of ethidium bromide in PBS), 10 µl of the NIT-1 cell suspension 
was transferred to a clean microscope slide, and a coverslip was placed on the suspension.  Using 
a fluorescence microscope with a FITC/TRITC filter, cells were scored for morphological 
evidence of apoptosis versus necrosis by visualization of the cell for both the color and the state 
of the nucleus, using a mixture of the DNA intercalating dyes acridine orange and ethidium 
bromide.  The criteria we used to score the cells after treatment were as follows: 100 cells 
(minimum) were scored into one of four categories: Viable cells with normal nuclei (green 
nuclei), necrotic cells with normal nuclei (orange nuclei), apoptotic cells with intact membranes 
(highly condensed green nuclei), and apoptotic cells with damaged membranes (highly 
condensed orange nuclei).  The percentages of the morphological categories were then 
calculated.  
3.9 GRP78 PEPTIDE LIBRARY 
Overlapping 15mer peptides of murine GRP78 (ID P20029) were synthesis by Mimotope 
(Clayton Victoria, Australia).  Peptides were pooled into groups of 12 or 13 peptides.  Peptide 
pools were assessed at 2.8, 1.4, and 0.7ug of peptide per well in T cell clone assays as previously 
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described in “T- and B-cell isolation, T cell clone culture, and antigen-specific T cell assay”.  
Individual and surrounding peptides were assayed if they stimulated the T cells in both pools, i.e. 
p32, p33, p34, p35, p36, p37, p38. 
3.10 ATP 8-AH SEPHAROSE PURIFICATION OF GRP78 
GRP78 was selectively purified by JenaBioscience ATP 8-AH sepharose.  NIT-1 cells treated 
with 5µM were lysed with Triton X-114 (87).  Lysates were dialyzed against 20 mM Tris pH 
7.5, 20 mM NaCl, 10 mM MgSO4, 14 mM 2-ME at 40C overnight in a (0.5 – 3 mL) 10K MWCO 
slide-a-lyzer with several buffer exchanges.  Dialyzed lysates were mixed with 1mL of ATP 8-
AH sepharose and incubated overnight at 40C on a rocking platform.  The columns were washed 
and ATP-binding proteins were eluted with 10-20mM ATP.  Eluted proteins were analyzed by 
silver stain, immunoblot, and T cell assay as described in “Immunoblot Analysis” and “T- and 
B-cell isolation, T cell clone culture, and antigen-specific T cell assay”.  Silver stain was 
preformed with Amersham Silver Stain Plus according to manufacture’s protocol. 
3.11 REMOVAL OF O-LINKED GLYCOSYLATION 
NIT-1 cells were treated with 5µM thapsigargin.  Lysates were prepared in RIPA buffer.  To 
remove sites of O-linked glycosylation cells were treated as described in Mansour et al (88).  
Briefly, lysates were incubated with 0.1M NaOH at 370C for 0 and 3 hours.  0.1M glacial acetic 
acid was added to neutralize NaOH.  Immunoblots and T cell assays were performed with lysates 
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as described in “Immunoblot Analysis” and “T- and B-cell isolation, T cell clone culture, and 
antigen-specific T cell assay”.  For immunoblot, anti-mouse O-linked N-acetylglucosamine 
antibody (CTD110.6, Abcam, Cambridge, MA; 1:1000) or Stressgen anti-GRP78 was used as 
primary antibody.  Goat anti-mouse and goat anti-rabbit were used as secondary antibodies, 
respectively. 
3.12 CITRULLINATION DETECTION ASSAY 
To detect citrullinated protein in our lysates, we used the anti-citrulline (modified) detection kit 
(Upstate, Lake Placid, NY) according to manufacture’s protocol.  Protein samples were 
separated on a 4-20% gradient SDS-PAGE gel using Mini-Protean II electrophoresis (Bio-Rad, 
Hercules, CA) at 150V for 1 h. Proteins were transferred onto 0.45µm charged PVDF 
membranes using a Mini Trans-Blot electrophoretic transfer apparatus (Bio-Rad) at 100V for 1 
hr at 4°C in 25mM Tris-Hcl, 192mM glycine, 10% methanol, pH=8.3.  Membranes were 
modified overnight in water bath at 37ºC in a 50/50 mixture of Reagent A and B.  Reagent A is 
0.025% FeCl3 in a solution of sterile, distilled water/98% H2SO4/85% H3PO4.  Reagent B is 0.5% 
2,3-butanedione monoxime, 0.25% antipyrine, 0.5M acetic acid.  After 4 washes with water, 
membranes were then block in 3% Milk-TBS (TBS-MLK) for 30 minutes.  Membranes were 
incubated for 30 minutes with Anti-citrulline (modified) antibody, which was diluted at 1:1000 
in TBS-MLK.  Two washes with water were followed with a 45 minutes incubation with goat 
anti-rabbit HRP conjugated IgG (1:5000).  The membranes were then washed twice with water, 
followed by a wash with TBS-0.05% Tween-20 for 3 minutes.  The membranes were washed 4 
times with water before bands were detected with ECL Plus. 
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4.0  GLUCOSE REGULATED PROTEIN 78 (GRP78): A CANDIDATE ANTIGEN FOR THE 
DIABETOGENIC T CELL CLONE, BDC-2.5. 
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4.1 INTRODUCTION 
Type 1 Diabetes (T1D) is initiated by T cell recognition of pancreatic beta cell antigens and is 
characterized by T cell-mediated leukocytic infiltrate into the pancreatic islets, beta cell 
destruction, and ultimately hyperglycemia.  It has been well established in T1D patients and 
recapitulated in animal models of T1D that human HLA class II  / mouse MHC II is a major 
determinant of susceptibility (55, 89).  The importance of MHC class II is reinforced by the fact 
that diabetogenic CD4+ T cells are absolutely critical for the initiation of T1D in open T cell 
repertoire animal models (85, 90).  Thus knowledge gained, regarding self-antigen interaction 
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with these class II molecules will provide insight into the events that precipitate the breakdown 
of self-tolerance in T1D.  The NOD mouse is a well-characterized model of T1D that closely 
resembles the human form of the disease.   
To investigate the role of CD4+ T cells and the autoantigens to which they respond in T1D, a 
panel of CD4+ Th1 T cell clones recognizing islet beta cells as antigen and able to rapidly cause 
diabetes in very young (<10 day-old) NOD recipients was produced (61, 85).  The properties of 
these T cell clones have been described in a number of publications and, in the case of one clone, 
BDC-2.5, a TCR-transgenic (91) model (92) has made possible a variety of in vivo studies (85).  
The CD4+ BDC-2.5 T cell clone responds to antigen in the form of whole mouse islet cells, or 
membrane preparations from beta tumor cells (βmem), presented in the context of IAg7 (62, 93). 
Although it has been 20 years since this clone was first reported, neither the natural 
peptide ligand nor the protein source of the peptide antigen has been identified. On the other 
hand, various peptide mimotopes that can stimulate activity of the BDC-2.5 clone or 2.5 TCR-Tg 
T cells have been reported.  Judkowski et al described a series of peptides that were able to 
induce responses of varying magnitude in T cells from the 2.5 TCR-Tg mice (94).  It was of note 
in this study that based on homology to a GAD peptide sequence, the authors speculated that 
GAD was the source of the natural antigen ligand for BDC-2.5.  Since other studies, however, 
have failed to confirm any antigenic activity with GAD, or sequential peptides from GAD, with 
the BDC-2.5 T cell clone, it is doubtful that GAD is the source of antigen for this clone (85).   
Yoshida et al reported on several peptide mimotopes, identified through screening of a 
combinatorial peptide library, that activated clones from two panels of NOD-derived CD4+ T cell 
clones isolated from two separate labs (95).  These peptides behaved as agonists, eliciting strong 
responses from several clones in the panels.  Since no homology could be found between 
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sequences in these mimotopes and peptides in data banks, proteins could not be identified as 
candidate antigens from this study. 
Despite extensive investigation, the events that trigger T1D remain unknown.  What is 
becoming evident in at risk individuals and in animal models is that events leading to the 
presentation of beta cell associated oligopeptide antigens to autoreactive T cells during the 
initiation of T1D may result from normal physiological actions during the development of beta 
cells or routine beta cell metabolic function.  The production of neo-antigens, coupled to 
defective APC function may be a recipe for beta cell selective autoimmunity (96) (57, 58, 97).  
T1D, as manifested in the NOD model, has been described as a progression through a series of 
checkpoints.  First there is the expansion of the autoreactive pool (checkpoint 1), followed by 
homing of the T cells to the pancreas (checkpoint 2), and finally the transition from peri-insulitis 
to invasive, destructive insulitis (checkpoint 3) (98).  To better understand the initiating events 
and the role of CD4+ T cells in the pathogenesis of T1D, I have utilized BDC-2.5 T cell clones, 
in a T cell:B cell model system, which I have termed Restricted Immune System via Adoptive 
Transfer (RISAT).  It is well established that long-lived B cells circulate through the blood and 
lymph nodes until they encounter their specific antigen that has been ferried to the T cell areas of 
the lymph node or spleen by macrophages and/or dendritic cells.  Interaction with antigen 
inhibits B cell migration and leads to BCR-specific internalization of antigen (99, 100).  Naïve 
antigen-specific Th cells are also activated in these locations, by antigen-presenting dendritic 
cells.  During T cell-dependent activation, an APC presents a processed antigen to a Th cell 
resulting in T cell priming.  When a B cell processes and presents the same antigen to the primed 
Th cell, it leads to formation of stable T and B cell conjugates, termed linked-recognition, 
including the interaction of CD40L and CD40 on the T cells and antigen-specific B cells, 
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respectively (101).  These signals induce B cells to proliferate and terminally differentiate into 
antibody-secreting cells.  By using only the BDC-2.5 T cell clone to provide help to B cells after 
immunization with a previously described (62) antigenic beta cell membrane preparation 
(βmem) in NOD.Rag-/- mice, I was able to utilize linked recognition to drive antigen specific 
antibody production.  The resultant serum contained an antibody that immunoprecipitated the 
ER-associated protein GRP78 within the βmem.  This study suggests that the BDC-2.5 T cell 
recognizes the autoantigen, GRP78, during the normal physiological process of ER stress in 
pancreatic beta cells. 
4.2 RESULTS 
 
4.2.1 Proof of concept: RISAT with the DO11.10 T cell.  
To test the RISAT model, the OVA-specific DO11.10 T cell receptor transgenic mouse model 
was utilized (102). CB17.scid mice, which lack T cells and mature B cells, were reconstituted 
with DO11.10 T-cells and BALB/c B-cells, followed 10 days after transfer, by immunization 
with either OVA or the non-related antigen PCC (Figure 4.1).   Again, by reconstituting the scid 
mice with a single T cell clone, an open repertoire of B cells and then immunizing the mice with 
their cognate antigen, through linked recognition the T cells should lend help to the B cells to 
produce IgG antibodies against the cognate antigen. 
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Figure 4.1  Timeline of transfers and immunization schedule for DO11.10 RISAT. 
 
Sera from the DO11.10 RISAT mice were collected prior to and after each immunization, 
and then screened for antibody production by Western blot analysis.  Antibody production in the 
DO11.10 RISAT model was detected after the first boost of whole OVA using a secondary 
antibody that is specific for the light chain of mouse IgG, and was absent prior to the adoptive 
transfer of DO11.10 T-cells and BALB/c B-cells and, before immunization.  Animals immunized 
with the irrelevant antigen PCC did not produce IgG light chain, supporting the linked 
recognition strategy (Figure 4.2).  Furthermore, animals immunized with OVA generated only 
OVA-specific antibodies that had no specific cross-reactivity to PCC (Figure 4.3). 
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Figure 4.2  Screening DO11.10 RISAT mouse serum for antibody production. To screen 
DO11.10 RISAT mouse serum for antibody production, sera from four mice (A-D) were run on a 
gradient gel and transferred to a PVDF membrane.  The membrane was probed with an anti-
mouse antibody to determine which mice (1-4) were producing antibodies after transfer of 
DO11.10 T-cells and BALB/c B-cells and immunization with whole OVA.  Control mice 
received DO11.10 T-cells and BALB/c B-cells and were immunized with PCC (pigeon 
cytochrome-c). Pre, before adoptive transfers and immunization; Post, after adoptive transfers of 
T-cells and B-cells, before immunization; 1st, after adoptive transfers and 1st immunization.  
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Figure 4.3  DO11.10 RISAT generated serum recognizes its cognate antigen, OVA. 50µg of 
whole OVA or PCC was immunoblotted against DO11.10 RISAT generated serum.  Mouse B 
serum was positive for antibody production; thus it was used for the immunoblot. Pre, before 
adoptive transfers and immunization; Post, after adoptive transfers of T-cells and B-cells, before 
immunization; 1st, after adoptive transfers and 1st immunization. 2nd, after 2nd immunization; 3rd, 
after 3rd immunization.  
 
4.2.2 RISAT-generated sera from NOD.Rag-/- mice immunoprecipitates GRP78 from 
βmem.   
The results of the DO11.10 RISAT experiment demonstrated that the RISAT system for antibody 
generation based on linked recognition would work.  After NOD.Rag-/- mice were populated with 
BDC-2.5 T cell clones and NOD derived B cells, I detected increased antibody production with 
each immunization with of βmem preparation (Figure 4.4).  There was antibody production 
present in the control lane, however, these antibodies were not specific to βmem (data not 
shown).  
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Figure 4.4  Screening for antibody production in the BDC-2.5 RISAT mice. To screen the 
BDC-2.5 RISAT generated serum for antibody production; sera were run on a gel and transferred 
to a PVDF membrane.  The membrane was probed with an anti-mouse antibody in order to 
determine if the BDC-2.5 RISAT mice (A, B, and C) were producing antibodies after 
reconstitution with both BDC-2.5 T cells and NOD B cells and immunization with βmem.  
Control sera are from mice that received only NOD B cells and immunized with βmem. 
 
 
Sera from RISAT mice were screened for antibody production against antigenic βmem 
and non-antigenic NIT-1 lysate.  Control mice did not produce antibodies that recognized protein 
in either βmem or NIT-1 lysate (data not shown).  Serum from BDC-2.5 RISAT mouse A 
produced βmem specific antibodies.  Therefore, it was used to perform a traditional immunoblot 
with NIT-1 lysates and βmem to determine which protein(s) were recognized by the immune 
serum. The serum recognized a protein at molecular weight 70kDa in the βmem fraction, but 
failed to respond strongly to any proteins in the NIT-1 lysate (Figure 4.5).   
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Figure 4.5  Immunoblot of NIT-1 lysate and βmem with BDC-2.5 RISAT serum. NIT-1 
lysate and βmem were separated by SDS-PAGE gel and transferred to a PVDF membrane.  The 
membrane were probed with BDC-2.5 RISAT serum from mouse A which was collected at 
various timepoints, pre., post, 1st, and 2nd.  Serum was diluted at 1:200. 
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Table 4.I  Identification of 70kDa protein band with MALDI-ToF. 
    Amino Acid 
position 
 
 
Observed 
Mr 
(expected) 
Mr 
(calculate
d) 
 
Δdaltons Start End Peptide Sequence 
1191.67 1190.67 1190.63 0.04 466 475 VYEGERPLTK 
1210.63 1209.62 1209.58 0.04 378 387 EFFNGKEPSR 
1316.69 1315.68 1315.68 0.00 523 533 NKITITNDQNR 
1329.70 1328.69 1328.61 0.08 328 337 FEELNMDLFR 
1397.84 1396.83 1396.78 0.05 623 634 ELEEIVQPIISK 
1430.73 1429.72 1429.68 0.04 103 114 TWNDPSVQQDIK 
1460.81 1459.80 1459.75 0.05 355 368 SDIDEIVLVGGSTR 
1512.80 1511.80 1511.74 0.05 326 337 AKFEELNMDLFR 
1528.80 1527.79 1527.74 0.05 326 337 AKFEELNMDLFR 
1536.85 1535.84 1535.79 0.05 140 153 TFAPEEISAMVLTK 
1552.84 1551.83 1551.79 0.04 140 153 TFAPEEISAMVLTK 
1566.84 1565.83 1565.77 0.05 62 75 ITPSYVAFTPEGER 
1588.92 1587.91 1587.85 0.06 354 368 KSDIDEIVLVGGSTR 
1604.90 1603.90 1603.86 0.04 125 139 TKPYIQVDIGGGQTK 
1659.92 1658.92 1658.89 0.03 199 214 IINEPTAAAIAYGLDK 
1677.87 1676.86 1676.80 0.06 83 97 NQLTSNPENTVFDAK 
1816.05 1816.05 1814.99 0.06 199 215 IINEPTAAAIAYGLDKR 
1836.99 1835.99 1835.93 0.06 449 465 SQIFSTASDNQPTVTIK 
1888.04 1887.03 1886.96 0.07 166 182 VTHAVVTVPAYFNDAQR 
1903.98 1902.98 1903.12 -0.14 1 18 MMKFTVVAAALLLLGAVR 
1934.08 1933.07 1933.01 0.07 476 493 DNHLLGTFDLTGIPPAPR 
1974.98 1973.98 1973.90 0.08 603 618 IEWLESHQDADIEDFK 
1999.16 1998.15 1998.08 0.07 494 511 GVPQIEVTFEIDVNGIIR 
2016.16 2015.15 2015.06 0.09 165 182 KVTHAVVTVPAYFNDAQR 
2149.07 2148.06 2147.99 0.07 308 325 IEIESRREGEDFSETLTR 
2174.13 2173.12 2173.03 0.09 603 620 IEWLESHQDADIEDFKAK 
2178.07 2177.07 2176.96 0.10 635 655 LYGSGGPPPTGEEDTSEKDEL 
 
Band immunoprecipitated and visualized with Gel Code Blue in Figure 4.6A and later 
identified in Figure 4.6B as GRP78 by immunoblot was excised from SDS-PAGE gel stained 
with Gel Code Blue.  MALDI-ToF was preformed on excised band.  Band was identified as 
GRP78 with a score of 191 with complete coverage using Matrix Science Mascot database-
searching program. 
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The BDC-2.5 RISAT generated serum was used in an immunoprecipitation assay with the βmem 
preparation.  Immunoprecipitated proteins were subjected to SDS-PAGE and then visualized by 
GelCode® Blue staining (Figure 4.6A).  A 70kDa band present on the gel was subjected to 
MALD-TOF analysis.  MALDI-TOF spectrometry and analysis of the peaks via the Matrix 
Science Mascot database-searching program determined the protein to be GRP78 with a high 
degree of probability (Table 4.I).   
The results from the MALDI-ToF analysis were also confirmed by Edman degradation 
with immunoprecipitated βmem protein with BDC-2.5 RISAT generated serum (data not 
shown). To demonstrate that the BDC-2.5 RISAT produced sera contained generated antibodies 
specific to GRP78, they were used as primary antibodies in an immunoprecipitation reaction 
with βmem protein.  The resultant immunoprecipitated protein was transferred to a PVDF-
membrane and probed with a commercially available antibody to GRP78 via immunoblot 
(Figure 4.6B). 
 
 
 
 
 
 
 61 
 
Figure 4.6 Immunoprecipitation to confirm that BDC-2.5 RISAT serum recognizes GRP78. 
A) Protein bands were visualized with Gel Code Blue.  Lane 1 (L1): βmem, L2: 
Immunoprecipitated βmem.  For immunoprecipitation, βmem was incubated with BDC-2.5 
RISAT generated serum.  Protein:antibody complexes were pulled down with Protein G and 
separated on a SDS-PAGE gel and stained with Gel Code Blue. B) Immunoblot of 
immunoprecipitated βmem.  Immunoprecipitated βmem was run out on a SDS-PAGE gel and 
transferred to a PVDF membrane, blocked and probed with Stressgen anti-GRP78 antibody.  
After incubation with an anti-rabbit antibody, a signal was detected using ECL Plus reagent. 
 
 
 
 
 
 
 62 
4.2.3 NOD and NOD.BDC-2.5 TCR-Tg mouse sera contain autoantibodies to GRP78.   
To confirm the immunoprecipitation results achieved with the RISAT-produced serum, I 
analyzed serum from different aged NOD and NOD.BDC-2.5 TCR-Tg mice to determine if they 
inherently produced autoantibodies to GRP78.  Figure 4.7A demonstrates that serum from 
female NOD mice display autoantibodies against numerous βmem proteins including GRP78 as 
early as 2 months of age.  This pattern of antibody reactivity would be expected since the 
standard NOD mouse has a full T and B cell repertoire that could potentially allow T cell 
reactivity to give help to a multitude of B cells in generating autoantibody synthesis.  
Interestingly, when I used serum from NOD.BDC-2.5 TCR-Tg mice as a primary antibody 
against βmem protein in a Western blot, autoantibody specificity against GRP78 was detected in 
these mice (Figure 4.7B).  These results demonstrate that both NOD and NOD.BDC-2.5 TCR-
Tg mice are capable of producing autoantibodies to GRP78, further confirming the relevance of 
the BDC-2.5 RISAT results and the potential for ER stress induction of autoantigen synthesis. 
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Figure 4.7  NOD and NOD.BDC-2.5 TCR Tg confirm anti-GRP78 results with BDC-2.5 
RISAT generated serum. A) Serum from NOD mice at 2, 4, and 6 months and B) serum from 
three different NOD.BDC-2.5 TCR Tg mice were screened for anti-GRP78 antibodies.  Letter 
designations above lanes represent individual mice.  For both panels, 50µg of βmem were run 
out on a SDS-PAGE preparative gel and transferred to a PVDF membrane.  Serum samples were 
diluted at 1:50 and 1:200 with 5% BSA in PBST and incubated overnight.  Then the membranes 
were incubated with an anti-mouse secondary antibody, which was detected with ECL Plus 
reagent. 
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4.2.4 E.coli expressed recombinant GRP78 did not elicit IFN-γ production from the BDC-
2.5 T cell clone.  
To confirm whether the BDC-2.5 T cell recognizes GRP78, commercially available recombinant 
GRP78 produced in E.coli was assessed for antigenicity in an in vitro T cell assay using the 
NOD.BDC-2.5 TCR-Tg mouse derived T cells.  Unexpectedly, the recombinant GRP78 failed to 
elicit a detectable IFN-γ response from NOD.BDC-2.5 TCR-Tg mouse derived T cells (data not 
shown), however, protein expression in E.coli differs from mammalian cells.  Hence, these 
differences, i.e. posttranslational modification of proteins, may alter the antigenic epitope of 
GRP78.  
4.2.5 Increased GRP78 production induced by ER stress, but not apoptosis, in the beta 
cell adenoma line NIT-1 and non-beta cell line HeLa enhances IFN-γ  expression by BDC-
2.5.  
The results suggest that the BDC-2.5 T cell responds to a GRP78 peptide in vivo and supports the 
production of GRP78-specific autoantibodies, but the clone does not react to a recombinant form 
of GRP78 in vitro.  As GRP78 is a key protein involved in the regulation of ER stress and since 
pancreatic beta cells are subject to secretory cell induced ER stress that results in a higher level 
of ER stress (73, 80, 103), I decided to test whether induction of ER stress in a beta cell 
insulinoma would lead to the necessary modification of the GRP78 and confer antigenic 
recognition for the BDC-2.5 T cell.  ER stress was induced in NIT-1 cells with thapsigargin to 
increase GRP78 synthesis.  Thapsigargin is an irreversible inhibitor of the ER Ca2+-ATPase 
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(104), which leads to elevated cytosolic calcium concentration within the cell, and ultimately 
leads to ER stress.  
 
 
 
 
Figure 4.8  Upregulation of GRP78 in NIT-1 and HeLa cells when treated with 
thapsigargin to induce ER stress. NIT-1 and HeLa cells were treated for 60 min with 0, 1, or 
5µM thapsigargin.  Cells were lysed with RIPA buffer.  50µg of lysate was separated on a SDS-
PAGE gel and transferred to a PVDF membrane, blocked and probed with anti-GRP78 or anti-
beta actin (as a loading control) antibody.  For NIT-1 cells, the Stressgen anti-GRP78 antibody 
was used.  For HeLa cells, the Santa Cruz anti-GRP78 (N-20) antibody was used as it recognizes 
human GRP78.  After the incubation with the secondary antibody, bands were detected using 
ECL Plus reagent.  For detection of BDC-2.5 GRP78, 50µg of the above mentioned lysate was 
immunoprecipitated with 50µl of BDC-2.5 TCR Tg serum. Protein:antibody complexes were 
pulled down with Protein G and was separated by SDS-PAGE gel. After transferring to a PVDF 
membrane, the membrane was probed with Santa Cruz anti-GRP78 (C-20) antibody. After 
incubation with the secondary antibody, bands were detected using ECL Plus reagent. 
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Figure 4.9  Upregulation of ER stress in NIT-1 and HeLa cells leads to an antigenic 
response by the BDC-2.5 T cell clone. In Vitro T Cell Assay: 2x104 BDC-2.5 T cell clones and 
5x105 irradiated (3500 RAD) NOD splenocytes were incubated with one thousand (1K) NIT-1 
cells treated with 0, 1, or 5µM thapsigargin or 25, or 50µM TPEN or 1K HeLa cells treated with 
0, 1, or 5µM thapsigargin or 25, or 50µM TPEN. On day three, supernatants were collected for 
IFN-γ ELISA.  The data are the average of three experiments. 
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Table 4.II  Death Assay with NIT-1 cells treated with thapsigargin or TPEN. 
 Live Cells Apoptotic Cells Membrane Damaged Cells 
Membrane 
Damaged/Dead 
Cells 
Control 58.3 0 21 18 
1µM Thaps. 61 1 21.6 32 
5µM Thaps. 59.6 1 17.6 23 
10µM TPEN 25 22.5 29.75 10.2 
50µM TPEN 30.75 16.5 20 33.6 
 
NIT-1 cells were treated with 1 or 5µM thapsigargin for 1hr or 10 or 50µM TPEN for 4hr.  Cells 
were then assessed by death assay using DNA intercalating dye mix.  100 cells were scored.  
Percentage for the morphological catergories, (1) viable cells with normal nuclei, (2) necrotic 
cells with normal nuclei, (3) apoptotic cells with intact membrane, and (4) apoptotic cells with 
damaged membrane, were calculated and reported. 
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Induction of ER stress in NIT-1 cells by thapsigargin treatment increases GRP78 expression 
(Figure 4.8), and positively correlates with an antigenic response from the BDC-2.5 T cell, as 
demonstrated by the increase in IFN-γ production compared to non-thapsigargin treated NIT-1 
cells (Figure 4.9).  An immunoprecipitation reaction using BDC-2.5 TCR Tg serum proved to 
pull down increasing amounts of the GRP78, from NIT-1 cells treated with increasing 
concentrations of thapsigargin compared to untreated NIT-1 lysate (Figure 4.8).  Since GRP78 is 
not unique to the islet beta cell, I asked whether the neo-antigenicity demonstrated by ER stress 
induction in the NIT-1 cells could also be demonstrated in non-beta cells by treating HeLa cells 
with thapsigargin and using them as a source of antigen in the BDC-2.5 T cell assay.  
Thapsigargin treated HeLa cells also elicited an antigenic response from BDC-2.5 as determined 
by elevated IFN-γ production (Figure 4.9).  This response was not as marked as in the NIT-1 
cells, however, the increase in overall GRP78 expression with thapsigargin treatment was not as 
robust as was demonstrated by the NIT-1 cells (Figure 4.8).  This may be attributed to the HeLa 
cells being not of islet origin or because they are human in origin.  In marked contrast, both non-
thapsigargin treated NIT-1 and HeLa cells were unable to stimulate the BDC-2.5 T cell clone 
above background levels (Figure 4.9).  Furthermore, to prove that this antigenicity induced by 
thapsigargin treatment was a result of ER stress and not apoptosis, NIT-1 cells were treated with 
TPEN, a zinc chelator capable of initiating apoptosis in cells (105).  TPEN-induced apoptosis of 
NIT-1 cells did not increase antigenicity for the BDC-2.5 T cell clone (Figure 4.9), even though 
10 and 50µM TPEN treatment resulted in 22.5% and 16.5% apoptotic cells, respectively.  
Interestingly, 1 and 5µM thapsigargin treatment only rendered 1% of NIT-1 cells apoptotic 
(Table 4.II) even though BDC-2.5-dependent IFN-γ synthesis increased 5 and 13-fold, 
respectively (Figure 4.9).  
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4.3 DISCUSSION 
Autoimmune diseases arise as a result of a complex interplay of factors, but it is often considered 
that the failure of the immune system to recognize ‘self’ leads to a breakdown in tolerance.  
Exploiting this breakdown in self-tolerance, I have developed a novel technique, termed RISAT, 
to reconstitute NOD.Rag-/- mice with BDC-2.5 T cells and an open repertoire of NOD B cells.  
Upon multiple immunizations with βmem, a previously described antigenic protein prep for the 
BDC-2.5 T cell (62, 85), I was able to induce the production of antibodies that 
immunoprepicated the ER stress induced protein GRP78 from βmem as identified by MALDI-
ToF analysis and Edman degradation.  Additional bands detected by BDC-2.5 RISAT antibodies 
were not identified by MALDI-ToF or Edman degradation analysis.  There are several reasons 
that I may not have been able to identify these proteins; these additional bands may be 
breakdown products or truncated proteins.  Due to the techniques used, the failure to identify the 
bands may be the result of N-terminal blockage that is commonly the result of acetyl groups 
(106).  Serum from non-immunized NOD.BDC-2.5 TCR Tg mice recognized GRP78 in the 
βmem preparation, confirming the RISAT-reconstitution results.   
To determine if purified GRP78 protein could elicit a response in vitro from BDC-2.5 T 
cells, I obtained a commercially available recombinant form of the protein produced in E. coli. 
The E. coli produced recombinant protein failed to stimulate the production of IFN-γ by the 
BDC-2.5 T cell clone above background levels in an in vitro T cell assay.  Since the RISAT data 
demonstrated that BDC-2.5 T cells could support T cell-dependent autoantibody production to 
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GRP78, I deduced that eukaryotic-dependent post-translational modification (PTM) of the 
protein might be necessary to confer antigenic recognition of GRP78 by BDC-2.5, an alteration 
to the protein that would be absent in a prokaryotic expression system.  Support for this 
hypothesis comes from work in Rheumatoid Arthritis (RA).  It is known that GRP78 is a target 
autoantigen in RA and both T and B cell autoreactivity has been demonstrated (83).  Moreover, 
Blass et al., (83) reported that 63% of the 400 RA patients tested for T cell reactivity to GRP78 
demonstrated specific T cell reactivity when challenged with biochemically purified GRP78 
from mammalian cells.  However, when these GRP78-specific T cells were screened against an 
E. coli derived GRP78 (the same commercially available source used in the BDC-2.5 T cell 
clone assays), there was no antigenic response, thus indicating that a PTM occurring in 
mammalian cells confers the antigenicity for this protein as an auto-antigenic target.  These 
results may explain the lack of response from BDC-2.5 with the recombinant produced GRP78.   
The results provide evidence that the BDC-2.5 T cell responds to GRP78 in vivo, but not 
to recombinant GRP78 in vitro.  I therefore decided to test the hypothesis that induction of ER 
stress in a beta cell line would lead to the necessary modification of the target protein, GRP78, 
and confer antigenic recognition for the BDC-2.5 T cell.  Since the BDC-2.5 T cells are not 
responsive towards NIT-1, a NOD-derived insulinoma cell line, I chose this line to test the 
hypothesis.  NIT-1 cells treated with the ER stress inducer thapsigargin, demonstrated an 
increase in GRP78 expression, concomitant with increased IFN-γ secretion from BDC-2.5 T 
cells after stimulation with thapsigargin treated NIT-1 cells.  Thapsigargin induced ER stress in 
HeLa cells also proved to elicit an IFN-γ response from the BDC-2.5 T cells, demonstrating that 
the ER stress induced upregulation of GRP78 confers antigenicity for the BDC-2.5, even in a 
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non-beta cell line. These results further support the hypothesis that a eukaryotic dependent 
modification of GRP78 is likely necessary for neo-antigenic recognition by BDC-2.5.   
Although some of the identified autoantigens in T1D have proven to be unique to islet 
beta cells, other antigens have been determined to be widely expressed proteins, including for 
example the recently identified T cell antigen, dystrophia myotonica kinase (DMK).  DMK is the 
antigen for the highly pathogenic CD8 T cell clones AI4 and its expression is not limited to islet 
beta cells (107).  Interestingly, the recognition of widely expressed proteins leading to specific 
beta cell destruction point to the unique physiology of beta cells as a possible predisposing factor 
to auto-aggressive T cell reactivity, (96, 97, 108) that is highlighted by an increase in continuous 
ER stress.  This further supports the idea that a unique post translational modification of the 
target protein GRP78 may confirm neoantigenicity.  These results, demonstrating that ER stress 
induction of the beta cell adenoma NIT-1 leads to induced antigenic recognition by the BDC-2.5 
T cell clone, point to the fascinating possibility that this physiological response in beta cell 
function during cellular stress may set in motion the activation of an autoreactive repertoire 
leading to beta cell destruction in individuals genetically predisposed for autoimmunity.  Recent 
reports have highlighted that many of the hypothesized environmental triggers that induce T1D 
through beta cell apoptosis, also lead to ER stress (70, 73, 96).  It is therefore tempting to 
speculate that at least for the diabetogenic T cell clone, BDC-2.5, that ER stress induction is 
necessary for antigenic recognition and adaptive immune effector function. 
The increased antigenicity observed with thapsigargin treated NIT-1 cells was not due to 
apoptosis since treatment of NIT-1 cells with the apoptosis-inducing agent TPEN did not 
increase the response of BDC-2.5 T cells.  These results support the hypothesis that cellular 
stresses, which disrupt normal ER function and activate the ER stress cascade, are a prerequisite 
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for antigenic-recognition by the BDC-2.5 T cell clone.  Bypassing ER stress induction through 
direct apoptosis may not allow for a threshold level of GRP78 to be attained for efficient 
activation of BDC-2.5 T cells.  Yet prolonged ER stress can eventually lead to apoptosis 
induction (71, 109, 110), which would facilitate the release of beta cell antigens that could be 
picked up by dendritic cells and ultimately presented to autoreactive T cells (96).  Expanding on 
those observations further, I emphasize that the induction of ER stress in beta cells initiates the 
release of antigen(s) and generates an appropriate threshold level of antigen that activates an 
autoreactive repertoire of T cells, such as the BDC-2.5 T cell.  Recently, Wang et al published 
that exposure of NIT-1 cells to streptozotocin (STZ) led to their upregulation of GRP78, as a 
protective mechanism against cell death (111). This effort to protect against beta cell death by 
inducing the ER stress protective program may be an inherent defense mechanism by the islet 
against environmental stressors.  A predisposition toward autoimmunity, however, may result in 
activating the autoimmune system to the related stress proteins, such as GRP78, breaking self-
tolerance, and initiating the self-destruction of the islet beta cells.  Further support for this theory 
comes from Coxsackie viral-mediated diabetes induction models in the NOD.BDC-2.5 TCR Tg 
mice.  Horwitz et al demonstrated that in the absence of direct viral-induced beta cell apoptosis, 
infection of NOD.BDC-2.5 TCR Tg mice with Coxsackie CB4 led to rapid development of 
diabetes by a non-specific bystander mechanism (112, 113).  I would speculate that viral-induced 
ER stress would increase GRP78 expression over a threshold and activate NOD.BDC-2.5 TCR 
Tg T cells to promote beta cell destruction (114).  
It has long been proposed that a number of environmental triggers (viral infection, drugs, 
and chemical inducers of oxidative stress) lead to the onset of T1D (114, 115), but a common 
link between these triggers has not been revealed.  The data demonstrates that a key ER-
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associated protein, GRP78, is an auto-antigenic target of the BDC-2.5 T cell clone in the RISAT-
reconstituted immune system, and after chemically inducing ER stress in the non-antigenic NIT-
1 cells.  In both cases, an elevation of GRP78 expression resulted in a concomitant increase in 
antigenic recognition by BDC-2.5 T cell clone.  In conclusion, these results strongly support ER 
stress as a mechanistic link for environmental triggers leading to the initiation of T cell-mediated 
beta cell recognition, destruction, and death in those individuals that are genetically predisposed 
to autoimmunity. 
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5.0  POSTTRANSLATIONAL MODIFICATION OF GLUCOSE REGULATED PROTEIN 78 
IS RECOGNIZED BY THE BDC-2.5 TCR-TG SERA. 
5.1 INTRODUCTION 
‘Conformational diseases’ or ‘folding diseases’ are diseases caused by the misfolding of cellular 
protein, which leads to protein aggregates that initiate ER stress.  It has become clear that ER 
stress plays a critical role in a number of diseases and efforts to elucidate the pathological 
contribution of ER stress are now under investigation.  ER stress induction occurs under a 
specific program as follows, 1) induction of ER chaperones through the unfolded protein 
response (UPR), 2) transitional attenuation, 3) ER associated degradation (69), and 4) apoptosis 
(70).   
IRE1 and PERK are held in the ER by GRP78 (Glucose regulated protein 78 kDa)/BIP 
(Immunoglobulin binding protein) and, upon ER stress induction, and released by GRP78 from 
the inner ER membrane to initiate the cascade of ER stress induced protein processing 
regulation.  ATF6 is activated by a two-step cleavage by Site-1 protease (S1P) and Site-2 
protease (S2P) and is the transcription factor necessary for the activation of new GRP78 m-RNA.  
IRE1 initiates XBP-1 to activate the transcription of target genes for molecular chaperones and 
accessory proteins such catalysts (68).  The increased number of chaperones is able to re-process 
the proteins that were unfolded or misfolded.  
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Alterations in ER stress response have been shown in neurodegenerative diseases, bipolar 
disorder, diabetes both T1D and T2D, atherosclerosis, ischemia, heart disease, liver disease, 
kidney disease and inflammatory diseases.  In T1D, inflammation plays a critical role in the 
disease progression and in some instances is associated with ER stress.  It has been reported that 
during inflammation NO-induced apoptosis, mediated by ER stress and CHOP, has been 
demonstrated in beta cells (70, 81, 82) (69, 75).  ER stress has also been reported to be important 
in autoimmunity.  In rheumatoid arthritis, GRP78 a key regulatory protein in the ER stress 
pathway as a target autoantigen with both T and B cell autoreactivity, with reports of up to 63% 
of the RA patients demonstrating a specific T cell reactivity when challenged with biochemically 
purified GRP78 from mammalian cells (83). 
Secretory cells, like islet beta cells and plasma cells, have a more developed ER in order 
to manage the continuous pressure of protein processing.  This leads to continuous ER stress 
with upregulation of chaperones and accessory proteins in order to maintain ER homeostasis 
(80).  In islet beta cells, disequilibrium in the ER leading to activation of ER stress occurs due to 
a number of different cellular events.  There is increasing evidence that cytokines, reactive 
oxygen species (ROS), viral infection, and drug/toxin exposure results in activation of ER stress.  
ROS has been shown to be important in beta cell death in type 1 diabetes.  Oyadomari et al 
demonstrated that the mouse insulinoma cell line, MIN6, produces nitric oxide (NO) in response 
to treatment with the cytokines, IL-1β, TNF-α, and IFN-γ.  The production of NO correlates with 
the activation of ER stress, as was demonstrated by the upregulation of GRP78, IRE1a, and 
PERK (74). 
Interestingly, caspase-12 mediated apoptosis has been theorized as a possible mechanism 
of antigen release for the mouse derived diabetogenic T cell clone BDC-2.5 T cell, a 
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diabetogenic CD4+ Th1 T cell clone derived from a diabetic non-obese diabetic (NOD) female 
mouse (96).  The BDC-2.5 recognizes islet beta cells and results in the induction of rapid 
diabetes in very young (<10 days-old) NOD recipients.  The BDC-2.5 T cell clone however, fails 
to initiate diabetes in adult NOD.scid mice unless co-transferred with CD8+ T cells from a 
diabetic NOD mouse.  Both the RISAT technique and the BDC-2.5 TCR-transgenic (91) model  
demonstrate the BDC-2.5 T cell lends help to B cells to drive the production of IgG antibodies 
specific for GRP78.  Additionally, the induction of GRP78 by the calcium flux caused by 
thapsigargin treatment leads to the BDC-2.5 T cell clone producing IFN-γ.  
There is evidence that post-translational modifications (PTM) can lead to the formation 
of a neoantigen.  PTM such as glycosylation, phosphorylation, and deamidation regulate the 
structure and function of proteins.  Phosphorylation regulates enzyme activity, activates signal 
transduction and is involved in protein-protein interactions.  Glycosylation is critical for protein 
stability, solubility, and secretion signals. Protein activity and interactions are also regulated by 
citrullination or deamidation.  
Although these PTM have a functional cellular role, the protein changes that are caused 
by the PTM can elicit an immune response.  Phosphorylation of lupus antigens is required for 
antibody recognition in the lupus mouse model, MRL/lpr (116).  Viruses have coat viral proteins 
with N-linked glycosylation sites enabling these proteins to go undetected by the immune 
system, however, when the viral proteins are deglycosylated target epitopes become available for 
immune detection (117).  There are cohorts of T cells that recognize citrullinated proteins in 
rheumatoid arthritis (RA) (118).  Antibodies specific for anti-citrullinated proteins are also 
present in RA patients (119).  These antibodies may arise from increased citrullinated proteins as 
a result of apoptotic events (33, 120).     
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There are several theories on the mechanism of PTM initiating an immune response (91).  
1) The absence of PTM in the thymus during T cell maturation does not allow for T cells which 
recognize PTM epitopes to be negatively selected against.  2) PTMs affect antigen processing 
and thus presentation of antigenic epitopes.  Cleavage sites necessary for antigenic epitope 
presentation can be blocked by PTM.    For example, this occurs with myelin basic protein 
(MBP), an autoantigen in multiple sclerosis (31).  Citrullination sites block cathepsin D from 
digesting MBP, thus altering how the protein is processed and presented by APCs to T cells (91, 
121).  3) The binding of antigens in the MHC-II groove is affected by PTMs.  Citrullinated RA 
antigens have a 20-100 times higher affinity to the RA-associated MHC-II molecules 
(DRB1*0404, *0401 and *0101) compared to unmodified antigens (122).  4) There is an 
association of PTM with cellular stress and apoptosis.  Utz et al demonstrated that proteins 
phosphorylated during stress inducing apoptosis are autoantibody targets in lupus (123).  PTM 
antigens are concentrated in blebs from apoptotic cells (124, 125) and may enable the levels of 
antigen to exceed the antigen threshold necessary for triggering the autoreactive immune 
response.  Hence, I explored the role of several different PTM to determine if they play a role in 
the development of GRP78 becoming antigenic for the BDC-2.5 T cell clone. 
In order to further understand how the global expressed GRP78 may lead to an organ-
specific destruction, I attempted to purify stress-induced GRP78.  Through immunoblot analysis, 
I was able to determine that GRP78 has sites of o-linked glycosylation and citrullination.  I also 
confirmed that GRP78 is phosphorylated on threonine and serine residues in NIT-1 cells.  
Additionally, I found the BDC-2.5 TCR-Tg antibodies recognize a subset of GRP78 which is 
modified with phosphoserine.  The data presented further elucidates how GRP78 develops into 
the neoantigen for the BDC-2.5 T cell clone. 
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5.2 RESULTS 
 
5.2.1 Individual peptides from GRP78 peptide library fail to stimulate the BDC-2.5 T cell 
clone. 
15mer peptides were synthesized for the GRP78 (Table 5.I).  The 161-15mers were pooled into 
26 sets of twelve to thirteen peptides (Table 5.II).  Pools were tested for antigenicity against the 
BDC-2.5 T cell clone.  Pools IX and XVI resulted in stimulation of IFN-γ production, however, 
when I looked at the common (p35) and surrounding peptides (p32 to p37), they failed to 
stimulate the BDC-2.5 T cell clone. 
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Table 5.I  Peptide Library for GRP78.   
ID # Sequence ID # Sequence ID # Sequence 
1 MMKFTVVAAALLLLGA 55 GEKNILVFDLGGGTFD 109 VMTKLIPRNTVVPTKK 
2 TVVAAALLLLGAVRAE 56 ILVFDLGGGTFDVSLL 110 LIPRNTVVPTKKSQIF 
3 AALLLLGAVRAEEEDK 57 DLGGGTFDVSLLTIDN 111 NTVVPTKKSQIFSTAS 
4 LLGAVRAEEEDKKEDV 58 GTFDVSLLTIDNGVFE 112 PTKKSQIFSTASDNQP 
5 VRAEEEDKKEDVGTVV 59 VSLLTIDNGVFEVVAT 113 SQIFSTASDNQPTVTI 
6 EEDKKEDVGTVVGIDL 60 TIDNGVFEVVATNGDT 114 STASDNQPTVTIKVYE 
7 KEDVGTVVGIDLGTTY 61 GVFEVVATNGDTHLGG 115 DNQPTVTIKVYEGERP 
8 GTVVGIDLGTTYSCVG 62 VVATNGDTHLGGEDFD 116 TVTIKVYEGERPLTKD 
9 GIDLGTTYSCVGVFKN 63 NGDTHLGGEDFDQRVM 117 KVYEGERPLTKDNHLL 
10 GTTYSCVGVFKNGRVE 64 HLGGEDFDQRVMEHFI 118 GERPLTKDNHLLGTFD 
11 SCVGVFKNGRVEIIAN 65 EDFDQRVMEHFIKLYK 119 LTKDNHLLGTFDLTGI 
12 VFKNGRVEIIANDGGN 66 QRVMEHFIKLYKKKTG 120 NHLLGTFDLTGIPPAP 
13 GRVEIIANDGGNRITP 67 EHFIKLYKKKTGKDVR 121 GTFDLTGIPPAPRGVP 
14 IIANDGGNRITPSYVA 68 KLYKKKTGKDVRKDNR 122 LTGIPPAPRGVPQIEV 
15 DGGNRITPSYVAFTPE 69 KKTGKDVRKDNRAVQK 123 PPAPRGVPQIEVTFEI 
16 RITPSYVAFTPEGERL 70 KDVRKDNRAVQKLRRE 124 RGVPQIEVTFEIDVNG 
17 SYVAFTPEGERLIGDA 71 KDNRAVQKLRREVEKA 125 QIEVTFEIDVNGILRV 
18 FTPEGERLIGDAAKNQ 72 AVQKLRREVEKAKRAL 126 TFEIDVNGILRVTAED 
19 GERLIGDAAKNQLTSN 73 LRREVEKAKRALSSQH 127 DVNGILRVTAEDKGTG 
20 IGDAAKNQLTSNPENT 74 VEKAKRALSSQHQARI 128 ILRVTAEDKGTGNKNK 
21 AKNQLTSNPENTVFDA 75 KRALSSQHQARIEIES 129 TAEDKGTGNKNKITIT 
22 LTSNPENTVFDAKRLI 76 SSQHQARIEIESFFEG 130 KGTGNKNKITITNDQN 
23 PENTVFDAKRLIGRTW 77 QARIEIESFFEGEDFS 131 NKNKITITNDQNRLTP 
24 VFDAKRLIGRTWNDPS 78 EIESFFEGEDFSETLT 132 ITITNDQNRLTPEEIE 
25 KRLIGRTWNDPSVQQK 79 FFEGEDFSETLTRAKF 133 NDQNRLTPEEIERMVN 
26 GRTWNDPSVQQKIKFL 80 EDFSETLTRAKFEELN 134 RLTPEEIERMVNDAEK 
27 NDPSVQQKIKFLPFKV 81 ETLTRAKFEELNMDLF 135 EEIERMVNDAEKFAEE 
28 VQQKIKFLPFKVVEKK 82 RAKFEELNMDLFRSTM 136 RMVNDAEKFAEEDKKL 
29 IKFLPFKVVEKKTKPY 83 EELNMDLFRSTMKPVQ 137 DAEKFAEEDKKLKERI 
30 PFKVVEKKTKPYIQVD 84 MDLFRSTMKPVQKVLE 138 FAEEDKKLKERIDTRN 
31 VEKKTKPYIQVDIGGG 85 RSTMKPVQKVLEDSDL 139 DKKLKERIDTRNELES 
32 TKPYIQVDIGGGGTKT 86 KPVQKVLEDSDLKKSD 140 KERIDTRNELESYAYS 
33 IQVDIGGGQTKTFAPE 87 KVLEDSDLKKSDIDEI 141 DTRNELESYAYSLKNQ 
34 IGGGQTKTFAPEEISA 88 DSDLKKSDIDEIVLVG 142 ELESYAYSLKNQIGDK 
35 QTKTFAPEEISAMVLT 89 KKSDIDEIVLVGGSTR 143 YAYSLKNQIGDKEKLG 
36 FAPEEISAMVLTKMKE 90 IDEIVLVGGSTRIPKI 144 LKNQIGDKEKLGGKLS 
37 EISAMVLTKMKETAEA 91 VLVGGSTRIPKIQQLV 145 IGDKEKLGGKLSSEDK 
38 MVLTKMKETAEAYLGK 92 GSTRIPKIQQLVKEFF 146 EKLGGKLSSEDKETME 
39 KMKETAEAYLGKKVTH 93 IPKIQQLVKEFFNGKE 147 GKLSSEDKETMEKAVE 
40 TAEAYLGKKVTHAVVT 94 QQLVKEFFNGKEPSRG 148 SEDKETMEKAVEEKIE 
41 YLGKKVTHAVVTVPAY 95 KEFFNGKEPSRGINPD 149 ETMEKAVEEKIEWLES 
42 KVTHAVVTVPAYFNDA 96 NGKEPSRGINPDEAVA 150 KAVEEKIEWLESHQDA 
43 AVVTVPAYFNDAQRQA 97 PSRGINPDEAVAYGAA 151 EKIEWLESHQDADIED 
44 VPAYFNDAQRQATKDA 98 INPDEAVAYGAAVQAG 152 WLESHQDADIEDFKAK 
45 FNDAQRQATKDAGTIA 99 EAVAYGAAVQAGVLSG 153 HQDADIEDFKAKKKEL 
46 QRQATKDAGTIAGLNV 100 YGAAVQAGVLSGDQDT 154 DIEDFKAKKKELEEIV 
47 TKDAGTIAGLNVMRII 101 VQAGVLSGDQDTGDLV 155 FKAKKKELEEIVQPII 
48 GTIAGLNVMRIINEPT 102 VLSGDQDTGDLVLLDV 156 KKELEEIVQPIISKLY 
49 GLNVMRIINEPTAAAI 103 DQDTGDLVLLDVCPLT 157 EEIVQPIISKLYGSGG 
50 MRIINEPTAAAIAYGL 104 GDLVLLDVCPLTLGIE 158 QPIISKLYGSGGPPPT 
51 NEPTAAAIAYGLDKRE 105 LLDVCPLTLGIETVGG 159 SKLYGSGGPPPTGEED 
52 AAAIAYGLDKREGEKN 106 CPLTLGIETVGGVMTK 160 GSGGPPPTGEEDTSEK 
53 AYGLDKREGEKNILVF 107 LGIETVGGVMTKLIPR 161 PPPTGEEDTSEKDEL 
54 DKREGEKNILVFDLGG 108 TVGGVMTKLIPRNTV   
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Table 5.II  Peptide Pool of GRP78 Peptide Library.   
 I II III IV V VI VII VIII IX X XI XII XIII 
XIV 1 2 3 4 5 6 7 8 9 10 11 12 13 
XV 14 15 16 17 18 19 20 21 22 23 24 25 26 
XVI 27 28 29 30 31 32 33 34 35 36 37 38 39 
XVI
I 40 41 42 43 44 45 46 47 48 49 50 51 52 
XVI
II 53 54 55 56 57 58 59 60 61 62 63 64 65 
XIX 66 67 68 69 70 71 72 73 74 75 76 77 78 
XX 79 80 81 82 83 84 85 86 87 88 89 90 91 
XXI 92 93 93 94 95 96 97 98 99 100 101 102 103 
XXI
I 104 105 106 107 108 109 110 111 112 113 114 115 116 
XXI
II 117 118 119 120 121 122 123 124 125 126 127 128 129 
XXI
V 130 131 132 133 134 135 136 137 138 139 140 141 142 
XV 143 144 145 146 147 148 149 150 151 152 153 154 155 
XVI 156 157 158 159 160 161        
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5.2.2 Freshly ATP 8-AH purified GRP78 is antigenic to the BDC-2.5 T cell clone. 
GRP78 was purified by taking advantages of its ATP binding domain. Freshly thapsigargin-
treated NIT-1 cells were lysed and subjected to an ATP column.  The resultant elution was silver 
stained, immunoblotted, and put into a BDC-2.5 T cell assay.  Purified GRP78 from 
Thapsigargin treated NIT-1 cells resulted in the stimulation of the BDC-2.5 T cell (Figure 5.1).   
Due to preparation-to-preparation variability in T cell assays, the same purified sample was 
utilized for a repeat assay (126).  After the preparation underwent a freeze-thaw, it was no longer 
antigenic for the BDC-2.5 T cell clone (data not shown).  I performed another set of biochemical 
assays, i.e. silver stains and immunoblots, to correlate with the results of the BDC-2.5 T cell 
assay.  Serendipitously, both silver stains (Figure 5.2) and immunoblots (Figure 5.3) 
demonstrated a loss of the high MW band that was present in the antigenic elution that correlated 
with the loss of IFN-γ production by the BDC-2.5 T cell clone.  
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Figure 5.1  BDC-2.5 T cell assay of purified GRP78 from NIT-1 thapsigargin treated 
lysates. NIT-1 cells were treated with thapsigargin for 1 hour at 5µM.  Cells were immediately 
lysed and purified using ATP 8-AH sepharose purification columns. Solid bars represent purified 
protein that was freshly assessed for antigenic by BDC-2.5 T cell assay, silver stain, and 
immunoblot.  ELISA for IFN-γ was preformed to detect activation of the BDC-2.5 T cell clone. 
Mimo, positive control; Thaps, 5uM thapsigargin treatment of NIT-1 cells. 
 
 
 
 
 
 
 
 
Purified GRP78 
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Figure 5.2  Silver Stain of purified GRP78 from NIT-1 thapsigargin treated lysates. NIT-1 
cells were treated with thapsigargin for 1 hour at 5µM.  Cells were immediately lysed and 
purified using ATP 8-AH sepharose purification columns. Lane A was freshly assessed for 
antigenic by BDC-2.5 T cell assay, silver stain, and immunoblot.  Lane B underwent a freeze-
thaw before assessment of antigenic by BDC-2.5 T cell assay, silver stain, and immunoblot. 
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Figure 5.3  Immunoblot of purified GRP78 from NIT-1 thapsigargin treated lysates. NIT-1 
cells were treated with thapsigargin for 1 hour at 5µM.  Cells were immediately lysed and 
purified using ATP 8-AH sepharose purification columns. Lane A was freshly assessed for 
antigenicity by BDC-2.5 T cell assay, silver stain, and immunoblot.  Membrane was probed with 
Santa Cruz (C-20) GRP78 antibody.  Lane B underwent a freeze-thaw before assessment of 
antigenicity by BDC-2.5 T cell assay, silver stain, and immunoblot.  Membrane was probed with 
Santa Cruz (N-20) GRP78 antibody. 
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Figure 5.4  Thapsigargin alters antibodies ability to detect GRP78 pulled down by BDC-2.5 
TCR-Tg. HeLa cells were treated with thapsigargin, 1 hour at either 0, 1, or 5 µM.  Cells were 
lysed.  Lysates were immunoprepicated with BDC-2.5 TCR-Tg serum overnight.  The pulled 
down (IP) proteins were separated along side whole cell lysate (WCL). Pulled down proteins 
were probed with Santa Cruz anti-GRP78 (N-20), (C-20), (H-129).  Whole cell lysates were 
probed with Santa Cruz anti-GRP78 (N-20) and actin.  Membranes were stained with ponceau S 
before blocking and probing. 
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5.2.3 Thapsigargin treatment alters antibody recognition to GRP78 in HeLa cells. 
Due to the poor cross-reactivity of the Stressgen anti-hamster GRP78 to human GRP78, I used 
anti-GRP78 antibodies from Santa Cruz to detect GRP78 in the human HeLa cell line.  I 
performed immunoprecipitations on thapsigargin treated HeLa with BDC-2.5 TCR-Tg serum.  
The BDC-2.5 TCR-Tg serum successfully pulled down a 70 kDa protein corresponding to 
GRP78 as shown with ponceau S stain (Figure 5.4).  Immunoblots of whole cell lysates showed 
that GRP78 was present in the lysate, however, attempts to probe the pulled down protein with 
three different Santa Cruz anti-GRP78 antibodies only yielded substantial detection of GRP78 in 
the untreated condition.  The various antibodies recognize varying degrees of the GRP78 from 
thapsigargin treated NIT-1 cells, however, none of the antibodies recognize all of the GRP78 
which is detected via ponceau S stain. 
5.2.4 N-linked and O-linked glycosylation does not play a role in induction of antigenicity. 
The inability to elicit a strong IFN-γ response with the overlapping peptides from GRP78 
combined with the antibody data, led us to speculate that a post translational modification of the 
protein was occurring that was responsible for the antigenic recognition by BDC-2.5. To assess 
the role of PTM via glycosylation, I treated NIT-1 cells with tunicamycin, an inhibitor of N-
linked glycosylation.  The results demonstrated that N-linked glycosylation was not responsible 
for induction of antigenicity, since there was no change in IFN-γ production (data not shown) 
when NIT-1 cells were treated with thapsigargin and tunicamycin and then co-cultured in a 
BDC-2.5 T cell assay.  In Figure 5.5, NIT-1 cells untreated and treated have numerous proteins 
that have sites of O-linked glycosylation; therefore I removed the O-linked glycosylation with 
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sodium hydroxide (Figure 5.5) and used the modified GRP78 protein in a T cell assay with 
BDC-2.5.  I was not able to correlate the removal of O-linked glycosylation with antigenicity 
from the BDC-2.5 T cell clone.   
 
 
 
 
 
Figure 5.5  Removal of O-linked glycosylation sites on GRP78. NIT-1 cells were treated with 
thapsigargin, 1 hour at 5µM.  Cells were lysed.  Lysates were incubated with sodium hydroxide 
to deglycosylate proteins.  Acetic acid was added to terminate the reaction either immediately 
after the addition of sodium hydroxide or after 3 hr incubation.  Lysates were separated.  
Membranes were probed with either Stressgen anti-GRP78 or anti-O-linked glycosylation 
antibody. 
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5.2.5 GRP78 is citrullinated in NIT-1 cells.  
With the current literature demonstrating the role of citrullination of proteins leading to increased 
self-recognition of proteins in RA, I explored this PTM as a possible mechanism of 
neoantigenicity.  Citrullinated GRP78 was detected in NIT-1 lysates, however, there was no 
correlation between untreated and 5mM thapsigargin (data not shown).  Additionally, the BDC-
2.5 TCR-Tg serum did not remove all the citrullinated GRP78 as there was still detection of 
citrullinated GRP78 in the supernatant (Figure 5.6A).  There was a dramatic change in the 
molecular weight of purified GRP78 following treatment with PAD, the enzyme that catalyzes 
the citrullination reaction (Figure 5.6B).   This did not correlate with changes in the antigenic 
response by the BDC-2.5 T cell clone (Figure 5.6C). 
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Figure 5.6  GRP78 is citrullinated. (A) NIT-1 cells were treated with thapsigargin, 1 hour at 
5µM.  Cells were lysed.  Lysates were immunoprepicated with BDC-2.5 TCR-Tg serum 
overnight.  The supernatants (sup) and pulled down (IP) proteins were separated.  GRP78 was 
detected using anti-GRP78 from Stressgen.  Citrullination was detected by use of Upstate 
Citrullination Detection Kit according to manufacture's instructions.  (B) Citrullinated GRP78 
was separated.  Membranes were stained with ponceau S to determine if there was a change in 
the molecular weight after PAD treatment. (un) untreated.  (cit) treated with PAD.  (C) 
Citrullinated GRP78 was assayed with BDC-2.5 T cell clone.  Commercial available purified 
GRP78 was treated with PAD to induce citrullination.  Mimotope was used as a positive control. 
 
5.2.6 Phosphorylation of serine residues.  
Through immunoblots, I determined the phosphorylation profile of GRP78 in NIT-1 and HeLa 
(Figure 5.7A).  GRP78 in both NIT-1 and HeLa contain phospho-tyrosine, threonine, and serine.  
I immunoprecipitated fresh lysates with the BDC-2.5 TCR Tg serum to determine if the serum 
antibodies were specific for a phosphorylation modification.  Probing back with a phospho-
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serine specific antibody, it was determined that the BDC-2.5 TCR Tg antibody recognizes a 
phospho-serine site(s) on GRP78 (Figure 5.7B).  
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Figure 5.7  Phosphoserine is specific to GRP78 pulled down by BDC-2.5 TCR-Tg. NIT-1 
and HeLa cells were treated with thapsigargin, 1 hour at 5µM.  Cells were lysed.  Untreated (un) 
and treated lysates were immunoprepicated with BDC-2.5 TCR-Tg serum overnight.  (A) Whole 
cell lysates, (B) supernatants (sup) and pulled down (IP) proteins were separated.  GRP78 was 
detected using anti-GRP78 (Santa Cruz N-20).  Phosphoserine (P-ser), phosphotyrosine (P-tyr) 
and phosphothreonine (P-thr) were detected with Sigma phospho-specific antibodies.  Actin was 
probed as a loading control for whole cell lysates. 
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5.3 DISCUSSION 
Although, the BDC-2.5 T cell clone helps B cells to produce antibody to GRP78, recombinant 
expressed GRP78 does not elicit a response by the BDC-2.5 T cell clone (unpublished data, 
Schreiner et al).  Freshly purified GRP78 from thapsigargin treated NIT-1 cells does lead to IFN-
γ production by the BDC-2.5 T cell clone, however, after a freeze-thaw the purified protein 
losses antigenicity.  Leustek et al determined that the in vivo and in vitro phosphorylation pattern 
of GRP78 is different (127).  In vivo GRP78 has sites of phosphothreonine and phosphoserine, 
however, upon certain purification methods or in vitro, sites of phosphoserine are lost.  There is 
evidence to support that the BDC-2.5 TCR-Tg antibodies clearly recognize a phosphoserine as 
phosphoserine GRP78 is void in the supernatant. 
It cannot be ruled out that multiple PTM are necessary for GRP78 becoming antigenic.  It 
has been proposed that citrullination leads to neoantigens because previously hidden epitopes 
become available.  Due to the enzymatic conversion of arginine to citrulline, there is a change in 
charge from positive to neutral.  This change leads to alterations in intramolecular protein 
binding causing the protein to unfold or fold differently.     
Through immunoblot analysis I confirmed previous studies, which demonstrate 
biochemically purified GRP78 is modified to contain phosphoserine (127-129).  It appears 
phosphoserine plays a critical role in the BDC-2.5 TCR-Tg serum being able to recognize 
GRP78 as the GRP78 remaining in the supernatant after clearing lysates with BDC-2.5 TCR-Tg 
sera is void of detectable phosphoserine.  The limitations of immunoblot does not allow us to 
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identify how many or what serines are phosphorylated.  Additionally, I was not able to determine 
if there are changes to phosphorylation sites with thapsigargin treatment.  Identification of 
specific posttransitional modifications for individual amino acids can be achieved by various 
mass spectrometry techniques.   
The BDC-2.5 TCR-Tg sera has poor affinity for denatured GRP78, evidence that it 
recognizes a conformational epitope.  Conformational epitopes are against 15-22 protein residues 
that are scattered over two or more discontinuous polypeptide segments (130, 131).  In infectious 
diseases, i.e. equine infectious anemia virus (EIAV) and parvovirus, the initial antibody response 
is to linear epitopes, however, over time there is a shift and selection for antibodies that 
recognize conformational epitopes indicative of a mature immune response (132, 133).  By the 
time a patient has clinical symptoms of diabetes, the immune response has been on going with 
the majority of beta cells already destroyed.  In some cases the immune response may have been 
initiated months or years prior (3).  Currently it is believed that in autoimmunity the majority of 
autoantibodies are to conformational epitope (131), though, it is not clear if autoimmune diseases 
go through the same linear to conformational maturation of antibody production as infectious 
diseases, due to the inability to properly monitor antibody production in autoimmune individuals. 
Epitope mapping using a GRP78 peptide library modified to contain phosphoserine is a 
way to identify whether the B cell epitope for the BDC-2.5 TCR-Tg sera is against a linear or 
conformational epitope.  The BDC-2.5 antibody may sufficiently bind a modified peptide to 
identify a portion of the B cell epitope.  Phage library screening has been successful in 
identifying conformational epitopes (130).  
It is unclear if the T cell receptor sees the same epitope as the B cell receptor.  The 
GRP78, which the B cell internalizes, processes, and presents to the BDC-2.5 T cell, contains 
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phosphoserines.  The binding surface that is antigenic to the BDC-2.5 may contain different sites 
of modification, such as phosphothreonine, citrulline, o-linked glycosylation, all of which I 
demonstrate occur in NIT-1 treated with thapsigargin, than that which are required for B cell 
recognition.  Presented within the antigen-binding groove of MHC molecules, T cell epitopes are 
short linear peptides (131).  A GRP78 peptide library that has been modified to contain PTMs 
should yield the identification of the BDC-2.5 T cell epitope along with the necessary PTM for 
antigenicity. 
Even though the window of disease transfer with the BDC-2.5 is early in mouse postnatal 
development, it remains to be determined what role the BDC-2.5 T cell and its cognate antigen, 
GRP78, plays in the initiation and progression of T1D. Furthermore, GRP78 and ER stress may 
be shown to the common link between the many potential environmental triggers proposed to 
initiate T1D.  Additionally, these findings may lead to potential therapies to eliminate the 
immune response to GRP78 during events of ER stress.  Other autoimmune diseases and ER 
stress disorders may benefit from application of potential therapies.   
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6.0  CONCLUSIONS 
6.1 PROPOSED MODEL OF GRP78 AND BDC-2.5 INTERACTION 
As the proposed model in Figure 6.1 shows, individuals with a genetic predisposition to 
developing diabetes have poor central and peripheral regulation of lymphocytes allowing 
autoreactive T and B cells in circulation.    Islet beta cells, as stated, are incredibly sensitive to 
ER perturbation and their continuous need to produce, package and secrete insulin upon glucose 
stimulated signaling provides a nonstop strain of protein production that is poised to ER stress.  
In combination with environmental triggers such as viral infection, chemical toxins, or food 
exposure, ER stress is further exacerbated leading to increased GRP78 production.  Changes in 
calcium levels in the ER lead to the release of GRP78 and the initiation of the UPR and ER 
dysregulation.  Increased levels of GRP78 are produced in an effort to control protein packaging 
and processing problems that occur during exposure to viruses, chemicals, and foods that 
inducescellular stresses such as oxidative stress.  The upregulation and PTM of GRP78 alters this 
protein enough for the immune system of genetically predisposed individuals to see this self-
protein as foreign.  Modified GRP78 is engulfed by APCs that process and present peptide 
fragments to circulating T cells.  The BDC-2.5 T cell becomes activated upon being presented its 
antigen peptide.  The activated BDC-2.5 T cell proliferates and produces IFN-γ leading to the 
recruitment of accessory cells to the islets, which initiates islet-beta cell destruction.  Following 
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presentation of its antigenic epitope, the activated T cell will lend help to the presenting B cell.  
The B cell matures into a plasma cell and secretes IgG antibodies.  The immune system will 
utilize these antibodies in antibody dependent cell cytotoxicity. 
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Figure 6.1  Proposed Model of GRP78 and BDC-2.5 Interaction. 
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6.2 EVIDENCE TO SUPPORT THE MODEL OF INTERACTION 
Identification of a common link between environmental triggers, i.e. viral infection, chemical 
and food exposure, would provide tremendous insight to the pathogenesis of T1D.  The presence 
of BDC-2.5 T cell’s antigen has been previously demonstrated in a number of environmental 
triggers with the activation of the BDC-2.5 T cell clone.  There is also increasing evidence for 
ER stress, more specially GRP78, playing a role in environmental triggers.  The cell attempts to 
protect itself from apoptosis initiated by environmental triggers leads to the upregulation of 
neoantigens, such as GRP78.  
Although GRP78 is expressed in numerous cell types, beta cells have inherently elevated 
levels of GRP78 as a result of their role as secretory cells constantly undergoing ER stress.  
Iwawaki et al demonstrated that the pancreas is the first organ with massive ER stress using the 
“ER stress-activated indicator” (ERAI) mouse model (68).  The onset of massive pancreatic ER 
stress coincided with the reported window in which the BDC-2.5 T cell clone can transfer 
diabetes in the NOD and NOD.scid mice.  After this window, initiation of cellular damage with a 
cotransfer of diabetic CD8+ T cells must accompany the BDC-2.5 T cells to lead to insulitis and 
hyperglycemia (85).  
Streptozotocin (STZ), a drug commonly used in TID research to abolish the beta cell 
mass, allows for synchronized onset of diabetes and may mimic the environmental trigger of 
chemical exposure.  The BDC-2.5 T cells activate and drain to the pancreatic lymph node within 
66 hours of being adoptively transferred into STZ treated NOD mice (96).  Exposure of NIT-1 
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cells to STZ leads to upregulation of GRP78 as a protective mechanism against cell death (111).  
Caspase-12 mediated death is necessary for the release of the BDC-2.5 T cell antigen as blocking 
of caspase-mediated death by using either benzyloxylcarbonyl-V-A-D-O-methyl fluoromethyl 
ketone (ZVAD) or caspase-12 knockout mice resulted in the BDC-2.5 T cell not becoming 
activated (96).  ER stress-apoptosis mediated through caspase-12 may be a mechanism that 
allows for the release and presentation of modified GRP78. 
The model lends rationale to my hypothesis that dysregulation in beta cell function as a 
result of various environmental triggers leads to increased ER stress, upregulation and PTM of 
GRP78, and subsequent aberrant recognition of GRP78 by the immune system that initiates T1D. 
Evidence that supports this comes from studies of viral infections, specifically coxsackievirus B4 
(CVB4), which have shown homology exists between viral and self-protein sequences, CVB4-
2C and GAD65 for instance (16, 17).  Furthermore, Horwitz et al demonstrates that the BDC-2.5 
TCR-Tg mice develop extensive insulitis and overt diabetes when infected with CVB4 (112).  
Although, the role of GRP78 has not been shown with CVB4 viral strain, GRP78 has been 
identified as a surface coreceptor in other coxsackeivirus (A9) infections (134). 
The mechanism of food exposure as an environmental trigger of T1D has been associated 
with BDC-2.5 T cell activation.  In studies performed by Turley et al, mice were fed dextran 
sodium sulfate (DSS) to mimic large intestine injury that occurs during inflammation caused by 
food exposure (135).  Following treatment with DSS, NOD mice were adoptively transferred 
with purified BDC-2.5/NOD T cells.  Even though the cellular damage occurred in the gut, 
activated BDC-2.5 T cells were located in the pancreatic lymph node.  Additionally, treatment of 
BDC-2.5/NOD animals with DSS resulted in a higher frequency of insulitis compared to control 
mice.  DSS is commonly used in colitis studies for diseases such Crohn’s, Celiac, and 
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inflammatory bowel disease (IBD).  Mice treated with DSS have increased GRP78 expression in 
their colons (136).  Examination of human colons from individuals with colitis and Crohn’s 
disease also demonstrates evaluated levels of GRP78 (137).  
The literature outlined above illustrates the strong parallels between the BDC-2.5 antigen, 
GRP78, ER stress and, T1D environmental triggers.  In order to confirm that ER stress, more 
specially GRP78, is the common link between T1D environmental triggers, future experiments 
should use the NOD mice and tissue from diabetic humans to dissect ER stress and GRP78’s role 
in the development of T1D. 
6.3 FUTURE DIRECTIONS OF RISAT TECHNIQUE 
The technique of Restricted Immune System via Adoptive Transfer (RISAT) was utilized to 
drive an antibody response specific to a single T cell clone.  A single T cell clone is adoptively 
transferred into an immunologically compatible immunodeficient mouse followed by an adoptive 
transfer of an open repertoire of immunologically compatible B cells.  The RISAT animal is then 
immunized with antigenic protein preparations to elicit an immune response from both the T and 
B cells.  B cells that receive T cell help will isotype switch to express IgG antibodies.  These IgG 
antibodies recognize only antigen that both the B cell and the single T cell clone bind and can be 
used to identify the T cell’s antigen. 
 There are still a number of diabetogenic T cell clones from the NOD mice with unknown 
antigens.  The BDC-6.9 T cell clone was developed with the BDC-2.5 T cell.  RISAT is being 
utilized to identify candidate autoantigens for the clone.  Preliminary results show antibodies that 
detect protein bands at 55 and 33 kDa (unpublished data). 
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The simplicity of the RISAT system allows for it to be utilized in various disease models.  
RISAT would allow for the identification of a primary T cell clone’s antigen without the 
expensive and time intensive techniques currently used, such as peptide or phage library 
screening (130, 131).  Additionally, antibodies produced in RISAT animals can be utilized in 
biochemical assays such as immunoprecipitations and immunoblots.  Skin lesions caused by 
infiltrating leukocytes characterize lupus.  The MRL.lpr mice spontaneously develop skin lesions 
between 3 and 6 months of age (138).  T cells isolated and expanded form these skin lesions can 
be used for RISAT in an immunologically compatible immunodeficient mouse.  RISAT mice 
would be immunized using skin cells from the lesion site.  The resulting antibodies would then 
be used to identify the isolated T cell antigen and expression patterns of the antigen through 
immunofluoresence, in addition to immunoblots to determine the antigen’s expression in other 
tissues.  
6.4 FUTURE DIRECTIONS FOR GRP78 AND TYPE 1 DIABETES 
To further confirm that GRP78 is the antigen for the BDC-2.5 T cell clone, additional BDC-2.5 
T cell assays with purified GRP78 from thapsigargin treated NIT-1 cells should be performed.  
Results should be correlated with silver stain and immunoblot to determine the purity of the 
purified GRP78.  Furter, if in vitro serine phosphorylation of non-antigenic purified GRP78 
causes these preparations to become antigenic that would provide strong evidence for the role of 
phosphorylation in the neo-antigenic of GRP78.  
Identification of GRP78 antibody epitopes will provide insight on how GRP78 becomes 
an autoantigen.  Immunoprecipitations with the BDC-2.5 TCR Tg serum demonstrate that sites 
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of phosphoserine are important to the recognition of GRP78 by the antibodies.  Additionally, 
binding sites of commercially available GRP78 antibodies are blocked by thapsigargin treatment 
(Figure 5.4).  Epitope mapping of the commercial antibody-binding sites will allow us to target a 
smaller region of the protein.  The existing peptide library shown in Table 5.I and 5.II can be 
used to epitope map the binding sites of the commercial antibodies as these antibodies are to 
unmodified peptide.  Briefly, epitope mapping can be conducted by immobilizing peptide pools 
to wells of an ELISA plate.  Commercial antibodies will be added to the well and allowed to 
bind to the immobilized peptides.  A secondary antibody will be used to detect which peptide 
pools the commercial antibodies are able to bind. 
As the T cell initiates the antigen-driven immune response, identification of the epitope 
responsible for the T cell response will allow for potential therapeutic targets.  With the 
identification of the commercial antibodies’ binding sites, there will be a limited number of 
peptides to further explore as candidate BDC-2.5 T cell epitopes.  These candidate peptides 
should be chemically modified to contain phosphoserine as this PTM is specific to a subset of 
GRP78 and then tested against the BDC-2.5 T cell clone to determine which candidate peptides 
contain the T cell epitope.  
The expression pattern of GRP78 should be determined, as this will provide information 
on the pathogenesis of how GRP78 is seen by the immune system.  It has been reported that 
GRP78 acts as a surface receptor.  If GRP78 is localized on the surface of the cells, this could be 
the mechanism that allows the immune system to recognize the resident ER protein.  The 
expression patterns of GRP78 in different mouse strains, i.e. NOD, ALR, NOR, are of particular 
interest.  Immunofluoresence analysis can be conducted with the BDC-2.5 TCR Tg serum.  
Additionally, it remains to be seen whether GRP78 is an autoantigen for human T1D.  Screening 
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of T1D patients at various stages, i.e. recent-onset, 1, and 5 years post diagnosis, and at-risk first 
degree relatives for autoantibodies and autoreactive T cells to unmodified and modified GRP78 
is critical to show the clinical relevance of my findings.  
The diabetes incidence is striking different in the BDC-2.5 TCR-Tg depending on the 
background which it is bred onto.  On the NOD background, only 10-15% of BDC-2.5/NOD 
animals spontaneously develop diabetes. By 3-5 weeks of age 100% of BDC-2.5 mice bred to 
the NOD.scid background develop diabetes (63).  The BDC-2.5/B6g7 begins to develop diabetes 
at 3 weeks of age, with the average onset at 6 weeks.  The diabetes incidence at 10 weeks is 
approximately 60% in the BDC-2.5/B6g7.  BDC-2.5/B6g7 animals that were free of diabetes at 10 
weeks of age remain resistant (64).  It would be interesting to determine if the B cell epitope is 
conserved in the different backgrounds. 
The complexity of trying to decrease GRP78 levels will make therapies directed at 
GRP78 expression less than ideal.  In attempts to deplete GRP78 with dsRNAi, Quian et al failed 
to completely deplete GRP78 protein levels (139).  There is a feedback mechanism that regulates 
GRP78.  I encountered this when I tried to block GRP78 expression with siRNA.  Immunoblots 
showed that the siRNA treatments actually upregulated GRP78, which correlated with increase 
IFN-γ production by the BDC-2.5 T cell clone when incubated with siRNA treated NIT-1 cells 
(data not shown).  Additionally, GRP78-/- (knockout) mice are embryonic lethal demonstrating 
how essential GRP78 is for cell survival (140).  Therapies that quell ER stress may have success, 
since the activation of ER stress is what leads to increased and modified GRP78, thus promoting 
antigenic recognition by the immune system.   
Although, the window of disease transfer with the BDC-2.5 T cell clone is early in 
postnatal development, the BDC-2.5 T cell clone has not been demonstrated to be the initiating T 
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cell for development of T1D.  Strategies to remove the BDC-2.5 T cell clone from the NOD 
mouse and determine if diabetes onset is altered should be explored to identify the relevance of 
GRP78 as an initiating antigen in T1D.  Use of the tetramer antibody that binds to the TCR of the 
BDC-2.5 T cell may be one way to selectively eliminate the BDC-2.5 T cell.  Complexing of 
FasL to the tetramer antibody could result in the selectively killing of the BDC-2.5 T cell 
allowing for the assessment of how diabetes progressions in the absence of the BDC-2.5 T cell.  
If GRP78 is shown to be an initiating antigen, vaccine development against this protein 
should yield protection against the development of T1D.  As improvements are made in 
identifying individuals that will become diabetic, a vaccine to build tolerance against early 
autoantigens would be beneficial.  A vaccine for GRP78 could potentially be used for other 
autoimmune diseases as RA, MS, and lupus have been shown to have GRP78 specific T cells 
(83, 125) (141).  
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6.5 FINDINGS OF THE THESIS 
 
In conclusion, the work presented in this thesis has demonstrated the following: 
 
(1) BDC-2.5 T cell drives antibody production to GRP78 both in the novel technique 
RISAT and in the BDC-2.5 TCR Tg mouse model.   
 
(2) The BDC-2.5 TCR-Tg antibody recognizes a subset of GRP78, which likely contains 
the posttranslational modification, phosphorylation, specifically serine phosphorylation.   
 
(3) Additionally, after induction of ER stress and upregulation of GRP78 by thapsigargin 
treatment, the non-antigenic NIT-1 cell line is able to initiate IFN-γ production from the BDC-
2.5 T cell clone.  
 
(4) The role of ER stress, GRP78, in the development of T1D is beginning to be 
elucidated and may be shown to be the common link between the various environmental triggers 
and the progression to T1D. 
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